VIICTR
Profiles
ORIT
Pediatrics RRO
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
CORTES, JORGE E
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
JORGE E CORTES
Title
Professor
Institution
MD Anderson
Department
Leukemia
Address
1400 Holcombe Blvd
Houston TX 77030-4008
vCard
Download vCard
Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
Newest
|
Oldest
|
Most Cited
|
Most Discussed
|
Timeline
|
Field Summary
|
Plain Text
PMC Citations
indicate the number of times the publication was cited by articles in PubMed Central, and the
Altmetric
score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.)
Fields
are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation
tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Miranda-Galvis M, Tjioe KC, Balas EA, Agrawal G,
Cortes JE
. Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review. Blood Adv. 2023 Nov 14; 7(21):6466-6491.
PMID:
37639318
.
Citations:
Sekeres MA, Montesinos P, Novak J, Wang J, Jeyakumar D, Tomlinson B, Mayer J, Jou E, Robak T, Taussig DC, Dombret H, Merchant A, Shaik N, O'Brien T, Roh W, Liu X, Ma W, DiRienzo CG, Chan G,
Cortes JE
. Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 2023 Oct; 37(10):2017-2026.
PMID:
37604981
; PMCID:
PMC10539167
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Garrett M, Knight B,
Cortes JE
, Deininger MW. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Med. 2023 09; 12(17):17981-17992.
PMID:
37553873
; PMCID:
PMC10524044
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Sasaki K, Morita K,
Kantarjian H
,
Garcia-Manero G
,
Jabbour E
, Ravandi F,
Konopleva M
,
Borthakur G
,
Wierda W
,
Daver N
,
Takahashi K
,
DiNardo C
, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS,
Cortes JE
. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):e369-e378.
PMID:
37690903
.
Citations:
Fields:
Neo
Neoplasms
Cortes JE
, Lipton JH, Kota V, Castagnetti F, Assouline S, Br?mmendorf TH, Leip E, Viqueira A, Gambacorti-Passerini C. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica. 2023 Jul 13.
PMID:
37439348
.
Citations:
Fields:
Hem
Hematology
Sahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A,
Cortes JE
, Kolhe R. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers (Basel). 2023 Jun 16; 15(12).
PMID:
37370824
; PMCID:
PMC10296552
.
Citations:
Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ, Sweet KL,
Cortes JE
, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clin Cancer Res. 2023 06 13; 29(12):2179-2183.
PMID:
36547666
; PMCID:
PMC10272032
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Mauro MJ, Hughes TP, Kim DW, Rea D,
Cortes JE
, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, G?mez-Garc?a de Soria V, le Coutre P, Mahon FX, Janssen JJWM, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023 05; 37(5):1048-1059.
PMID:
36949155
; PMCID:
PMC10169635
.
Citations:
3
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Swaminathan M,
Cortes JE
. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol. 2023; 14:20406207231154708.
PMID:
36845850
; PMCID:
PMC9943952
.
Citations:
1
Hochhaus A, R?a D, Boquimpani C, Minami Y,
Cortes JE
, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garc?a-Guti?rrez V, Kapoor S, Allepuz A, Quenet S, B?doucha V, Mauro MJ. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023 03; 37(3):617-626.
PMID:
36717654
; PMCID:
PMC9991909
.
Citations:
5
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cortes JE
, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K, Yocolly A. Health care resource utilization in 3L?+?patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ. 2023 Jan-Dec; 26(1):915-923.
PMID:
37431294
.
Citations:
Fields:
Hea
Health Services
Translation:
Humans
Cortes JE
, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
PMID:
36524980
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, R?cher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P,
Mohamed H
,
Cortes JE
. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2022 Nov 09.
PMID:
36370742
.
Citations:
15
Fields:
Hem
Hematology
Neo
Neoplasms
Cortes JE
, Lin TL, Asubonteng K, Faderl S, Lancet JE, Prebet T. Efficacy and safety of CPX-351 versus 7?+?3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022 10 26; 15(1):155.
PMID:
36289532
; PMCID:
PMC9598030
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Wang SA, Bagg A, Barbui T, Branford S,
Bueso-Ramos CE
,
Cortes JE
, Dal Cin P,
DiNardo CD
, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Godley LA, Gotlib J, Hobbs GS, Hoffman R,
Jabbour EJ
, Larson RA, Le Beau MM, Loh ML, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Tefferi A, Kvasnicka HM, Dombret H, Gianelli U, G?kbuget N, Hellstr?m-Lindberg E, Kiladjian JJ, L?wenberg B, Macintyre E, Thiele J, D?hner H. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
PMID:
35767897
; PMCID:
PMC9479031
.
Citations:
Fields:
Hem
Hematology
Casey M, Odhiambo L, Aggarwal N, Shoukier M, Garner J, Islam KM,
Cortes JE
. Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk? J Clin Oncol. 2022 Nov 10; 40(32):3719-3729.
PMID:
35944216
.
Citations:
Coughlin SS, Ayyala DN, Stewart JL,
Cortes JE
. Social needs and health-related quality of life among hematologic cancer survivors. Support Care Cancer. 2022 Nov; 30(11):8919-8925.
PMID:
35895158
.
Citations:
Fields:
Neo
Neoplasms
Pal
Palliative Care
Breccia M,
Jabbour E
, Mauro M,
Cortes JE
, Garc?a-Guti?rrez V. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022 07 11; 15(1):90.
PMID:
35818053
; PMCID:
PMC9272596
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
PH
Public Health
Cortes JE
, Milojkovic D, Gambacorti-Passerini C, Clark RE, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW, BFORE study investigators, Br?mmendorf TH, le Coutre P, Garcia-Gutierrez V, Hochhaus A. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 07; 36(7):1825-1833.
PMID:
35643868
; PMCID:
PMC9252917
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Lipton JH, Gambacorti-Passerini C, Deininger MW,
Cortes JE
, Br?mmendorf TH, Garcia-Guti?rrez V. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022 11; 56:100968.
PMID:
35570071
.
Citations:
Fields:
Hem
Hematology
Takahashi N,
Cortes JE
, Sakaida E, Ishizawa K, Ono T, Doki N, Matsumura I, Rosti G, Ono C, Ohkura M, Tanetsugu Y, Viqueira A, Garc?a-Guti?rrez V, Br?mmendorf TH. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun; 115(6):838-851.
PMID:
35235189
.
Citations:
Fields:
Hem
Hematology
Translation:
Humans
Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Kim DDH, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L,
Cortes JE
, Aimone P, Allepuz A, Quenet S, R?a D, Abdo A, Fogliatto LM, le Coutre P, Saussele S, Garc?a-Guti?rrez V, B?doucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 11 25; 138(21):2031-2041.
PMID:
34407542
.
Citations:
12
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Kota V, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, Leip E, Crescenzo RJ, Ferdinand R,
Cortes JE
, Br?mmendorf TH. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome?positive leukemias. Leuk Res. 2021 12; 111:106690.
PMID:
34673442
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Chien KS, Kim K, Nogueras-Gonzalez GM,
Borthakur G
,
Naqvi K
,
Daver NG
, Montalban-Bravo G,
Cortes JE
,
DiNardo CD
,
Jabbour E
,
Alvarado Y
,
Andreeff M
,
Bose P
,
Jain N
,
Kadia TM
, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA,
Kantarjian HM
,
Garcia-Manero G
. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.
PMID:
34340254
.
Citations:
4
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Swaminathan M,
Kantarjian HM
, Levis M, Guerra V,
Borthakur G
,
Alvarado Y
,
DiNardo CD
,
Kadia T
,
Garcia-Manero G
,
Ohanian M
,
Daver N
,
Konopleva M
,
Pemmaraju N
,
Ferrajoli A
,
Andreeff M
,
Jain N
,
Estrov Z
,
Jabbour EJ
,
Wierda WG
, Pierce S, Pinsoy MR, Xiao L, Ravandi F,
Cortes JE
. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
PMID:
33853292
; PMCID:
PMC8327731
.
Citations:
11
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Lin TL, Uy GL, Ryan RJ, Faderl S, Lancet JE. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7?+?3 in older adults with newly diagnosed high-risk/secondary AML. J Hematol Oncol. 2021 07 13; 14(1):110.
PMID:
34256819
; PMCID:
PMC8276472
.
Citations:
2
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Heuser M, Smith BD, Fiedler W, Sekeres MA, Leber B, Merchant A, Papayannidis C, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G,
Cortes JE
, Montesinos P, P?rez-Sim?n JA. Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 Jul; 100(7):1917-1918.
PMID:
33978823
; PMCID:
PMC8496603
.
Citations:
Fields:
Hem
Hematology
Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S,
Cortes JE
. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
PMID:
34171279
.
Citations:
6
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Saxena K,
Jabbour E
, Issa G, Sasaki K, Ravandi F, Maiti A,
Daver N
,
Kadia T
,
DiNardo CD
,
Konopleva M
,
Cortes JE
, Yilmaz M, Chien K, Pierce S,
Kantarjian H
, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94.
PMID:
34130720
; PMCID:
PMC8204504
.
Citations:
3
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, Ohkura M, Ono C, Viqueira A,
Cortes JE
, Br?mmendorf TH. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021 Jul; 114(1):65-78.
PMID:
33851349
.
Citations:
2
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Morita K,
Kantarjian HM
, Sasaki K, Issa GC,
Jain N
,
Konopleva M
, Short NJ,
Takahashi K
,
DiNardo CD
,
Kadia TM
,
Garcia-Manero G
,
Daver N
, Montalban Bravo G,
Cortes JE
, Ravandi F,
Jabbour E
. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021 08 01; 127(15):2641-2647.
PMID:
33823073
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W,
Ning J
, Short NJ,
Ohanian M
,
Cortes JE
,
Jabbour EJ
, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica. 2021 04 01; 106(4):1097-1105.
PMID:
33297667
; PMCID:
PMC8586820
.
Citations:
3
Fields:
Hem
Hematology
Translation:
Humans
Animals
Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S,
Cortes JE
, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 03 23; 5(6):1719-1728.
PMID:
33724305
; PMCID:
PMC7993093
.
Citations:
5
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Cortes JE
,
Kantarjian HM
, Mauro MJ, An F, Nick S, Leip E, Gambacorti-Passerini C, Br?mmendorf TH. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. Eur J Haematol. 2021 Jun; 106(6):808-820.
PMID:
33638218
.
Citations:
1
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Heuser M, Smith BD, Fiedler W, Sekeres MA, Leber B, Merchant A, Papayannidis C, Hoang CJ, O'Brien T, Ma WW, Zeremski M, O'Connell A, Chan G,
Cortes JE
, Montesinos P, P?rez-Sim?n JA. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021 May; 100(5):1181-1194.
PMID:
33740113
; PMCID:
PMC8043884
.
Citations:
6
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Maiti A, Rausch CR,
Cortes JE
,
Pemmaraju N
,
Daver NG
, Ravandi F,
Garcia-Manero G
,
Borthakur G
,
Naqvi K
,
Ohanian M
, Short NJ,
Alvarado Y
,
Kadia TM
,
Takahashi K
, Yilmaz M,
Jain N
,
Kornblau S
, Montalban Bravo G, Sasaki K,
Andreeff M
, Bose P,
Ferrajoli A
, Issa GC,
Jabbour EJ
, Masarova L, Thompson PA, Wang S,
Konoplev S
, Pierce SA,
Ning J
, Qiao W, Welch JS,
Kantarjian HM
,
DiNardo CD
,
Konopleva MY
. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898.
PMID:
32499238
; PMCID:
PMC7927994
.
Citations:
13
Fields:
Hem
Hematology
Translation:
Humans
Yilmaz M, Alfayez M,
DiNardo CD
,
Borthakur G
,
Kadia TM
,
Konopleva MY
,
Loghavi S
, Kanagal-Shamanna R,
Patel KP
,
Jabbour EJ
,
Garcia-Manero G
,
Pemmaraju N
, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G,
Takahashi K
, Assi R, Alotaibi AS,
Ohanian M
,
Andreeff M
,
Cortes JE
,
Kantarjian HM
, Ravandi F,
Daver NG
. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34.
PMID:
33618754
; PMCID:
PMC7901199
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Abou Dalle I,
Kantarjian HM
, Ravandi F,
Daver N
, Wang X,
Jabbour E
,
Estrov Z
,
DiNardo CD
,
Pemmaraju N
,
Ferrajoli A
,
Jain N
, Wang SA, Jammal N,
Borthakur G
,
Naqvi K
, Pelletier S, Pierce S,
Andreeff M
,
Garcia-Manero G
,
Cortes JE
,
Kadia TM
. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
PMID:
33449377
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Mehta P. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021 04 01; 96(4):493-507.
PMID:
33368536
; PMCID:
PMC7986910
.
Citations:
4
Fields:
Hem
Hematology
Translation:
Humans
Coughlin SS, Klaassen Z, Vernon M, Tingen MS,
Cortes JE
. Knowledge of prostate cancer among African American men: A systematic review. Prostate. 2021 02; 81(3):202-213.
PMID:
33368465
.
Citations:
3
Fields:
Uro
Urology
Translation:
Humans
Assi R,
Kantarjian H
, Keating M,
Pemmaraju N
,
Verstovsek S
,
Garcia-Manero G
, Ravandi F,
Borthakur G
, Dahl J,
Jabbour E
,
Cortes JE
. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917.
PMID:
33283580
.
Citations:
1
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R,
Loghavi S
,
Kadia TM
,
DiNardo CD
,
Borthakur G
,
Konopleva M
, Pierce SA, Wang SA, Tang G, Guerra V, Samra B,
Pemmaraju N
,
Jabbour E
, Short NJ, Issa GC,
Ohanian M
,
Garcia-Manero G
,
Bhalla KN
,
Patel KP
,
Takahashi K
,
Andreeff M
,
Cortes JE
,
Kantarjian HM
, Ravandi F,
Daver N
. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
PMID:
33681815
; PMCID:
PMC7935111
.
Citations:
9
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Jillella AP,
Cortes JE
, Kota VK. Optimizing management of acute leukemia in community centers and when to refer. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):123-128.
PMID:
33275676
; PMCID:
PMC7727530
.
Citations:
Fields:
Hem
Hematology
Translation:
Humans
Sasaki K,
Jabbour EJ
, Ravandi F,
Konopleva M
,
Borthakur G
,
Wierda WG
,
Daver N
,
Takahashi K
,
Naqvi K
,
DiNardo C
, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J,
Garcia-Manero G
,
Cortes JE
. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021 02 01; 96(2):241-250.
PMID:
33180322
; PMCID:
PMC9022629
.
Citations:
4
Fields:
Hem
Hematology
Translation:
Humans
Borthakur G
, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN,
Pemmaraju N
,
Bueso-Ramos C
,
Cortes JE
,
Andreeff M
. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259.
PMID:
33270904
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Cortes JE
, de Lima M, Estey EH, Giralt SA, Venditti A, Wang ES, Dombret H, Montesinos P, R?llig C. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020 10 15; 13(1):137.
PMID:
33059764
; PMCID:
PMC7559451
.
Citations:
2
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Animals
Yilmaz M, Alfayez M,
DiNardo CD
,
Borthakur G
,
Kadia TM
,
Konopleva MY
,
Loghavi S
, Kanagal-Shamanna R,
Patel KP
,
Jabbour EJ
,
Garcia-Manero G
,
Pemmaraju N
, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G,
Takahashi K
, Assi R, Alotaibi AS,
Ohanian M
,
Andreeff M
,
Cortes JE
,
Kantarjian HM
, Ravandi F,
Daver NG
. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
PMID:
33032648
; PMCID:
PMC7542942
.
Citations:
7
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Ganguly S,
Cortes JE
, Levis MJ, Martinelli G, Perl AE, Russell NH, Arunachalam M, Santos CD, Gammon G, Lesegretain A, Mires DE, Pham H, Wang Y, Khaled SK, Kr?mer A. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplant Cell Ther. 2021 02; 27(2):153-162.
PMID:
33017662
.
Citations:
4
Fields:
Hem
Hematology
Tra
Transplantation
Translation:
Humans
Cortes JE
, Candoni A, Clark RE, Leber B, Vyas P, Zeidan AM, Heuser M, Montesinos P. Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leuk Lymphoma. 2020 12; 61(14):3287-3305.
PMID:
32967493
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Yilmaz M,
Kantarjian HM
, Toruner G, Yin CC, Kanagal-Shamanna R,
Cortes JE
, Issa G, Short NJ,
Khoury JD
,
Garcia-Manero G
, Ravandi F,
Kadia T
,
Konopleva M
,
Wierda WG
,
Jain N
,
Estrov Z
, Sasaki K, Pierce S, O'Brien SM,
Jabbour EJ
. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
PMID:
32955970
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Cortes J
, Podoltsev N,
Kantarjian H
,
Borthakur G
, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99.
PMID:
32951163
.
Citations:
5
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Mughal TI,
Pemmaraju N
, Psaila B, Radich J,
Bose P
, Lion T, Rampal R, Jain T, Verstovsek S, Yacoub A,
Cortes JE
, Mesa R, Saglio G, van Etten RA, Kiladjian JJ. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2020 Dec; 38(5):654-664.
PMID:
32592408
; PMCID:
PMC8895354
.
Citations:
2
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Lin S, Shaik N, Chan G,
Cortes JE
, Ruiz-Garcia A. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. Cancer Chemother Pharmacol. 2020 10; 86(4):451-459.
PMID:
32885274
; PMCID:
PMC7515941
.
Citations:
1
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Borthakur G
,
Zeng Z
,
Cortes JE
, Chen HC, Huang X,
Konopleva M
, Ravandi F,
Kadia T
,
Patel KP
,
Daver N
, Kelly MA, McQueen T, Wang RY,
Kantarjian H
,
Andreeff M
. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303.
PMID:
32697348
.
Citations:
7
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Jamieson C, Martinelli G,
Cortes JE
, Papayannidis C. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia. Blood Cancer Discov. 2020 Sep; 1(2):134-145.
PMID:
34661144
; PMCID:
PMC8447269
.
Citations:
5
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Solem CT, Bell TJ, Kwon Y, Cappelleri JC, Johnson C, Bhattacharyya H, Hoang CJ,
Cortes JE
. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer. 2020 10 01; 126(19):4315-4321.
PMID:
32697335
; PMCID:
PMC7540307
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes JE
, Heidel FH, Fiedler W, Smith BD, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M, Robak T, Montesinos P. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 07 14; 13(1):92.
PMID:
32664995
; PMCID:
PMC7362563
.
Citations:
12
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Alfayez M, Issa GC,
Patel KP
, Wang F, Wang X, Short NJ,
Cortes JE
,
Kadia T
, Ravandi F, Pierce S, Assi R,
Garcia-Manero G
,
DiNardo CD
,
Daver N
,
Pemmaraju N
,
Kantarjian H
,
Borthakur G
. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.
PMID:
32561839
.
Citations:
6
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Ohanian M
,
Kantarjian HM
, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM,
Jabbour E
, Abruzzo L,
Verstovsek S
,
Borthakur G
, Ravandi F,
Garcia-Manero G
, Tamamyan G,
Champlin R
, Pierce S,
Ferrajoli A
,
Kadia T
,
Cortes JE
. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Jun 17.
PMID:
32557828
.
Citations:
1
Fields:
Hem
Hematology
Issa GC,
Kantarjian HM
, Xiao L,
Ning J
,
Alvarado Y
,
Borthakur G
,
Daver N
,
DiNardo CD
,
Jabbour E
,
Bose P
,
Jain N
,
Kadia TM
,
Naqvi K
,
Pemmaraju N
,
Takahashi K
,
Verstovsek S
, Andreeff M,
Kornblau SM
,
Estrov Z
,
Ferrajoli A
,
Garcia-Manero G
,
Ohanian M
,
Wierda WG
, Ravandi F,
Cortes JE
. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
PMID:
32546726
.
Citations:
3
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Br?mmendorf TH. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol. 2020 May 29; 9(2):IJH26.
PMID:
33005329
; PMCID:
PMC7510513
.
Citations:
5
Lee JH, Faderl S, Pagel JM, Jung CW, Yoon SS, Pardanani AD, Becker PS, Lee H, Choi J, Lee K, Kim M,
Cortes JE
. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2020 05 12; 4(9):2032-2043.
PMID:
32396615
; PMCID:
PMC7218422
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Samra B, Richard-Carpentier G,
Kadia TM
, Ravandi F,
Daver N
,
DiNardo CD
, Issa GC,
Bose P
,
Konopleva MY
, Yilmaz M,
Ohanian M
,
Borthakur G
,
Garcia-Manero G
, Pierce S,
Cortes JE
,
Kantarjian H
, Short NJ. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47.
PMID:
32366832
; PMCID:
PMC7198507
.
Citations:
2
Fields:
All
Allergy and Immunology
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Maiti A,
Kantarjian HM
, Popat V,
Borthakur G
,
Garcia-Manero G
,
Konopleva MY
,
DiNardo CD
,
Verstovsek S
,
Andreeff M
,
Kadia TM
, Ajufo HO, Goswamy RV, Blanco C, Velasquez M,
Daver NG
,
Pemmaraju N
, Pierce SR,
Wierda WG
,
Kornblau SM
, Ravandi F,
Cortes JE
. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699.
PMID:
32330243
; PMCID:
PMC7189295
.
Citations:
1
Fields:
Hem
Hematology
Translation:
Humans
Maiti A, Franquiz MJ, Ravandi F,
Cortes JE
,
Jabbour EJ
, Sasaki K, Marx K,
Daver NG
,
Kadia TM
,
Konopleva MY
, Masarova L,
Borthakur G
,
DiNardo CD
,
Naqvi K
, Pierce S,
Kantarjian HM
, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573.
PMID:
32289808
; PMCID:
PMC7839068
.
Citations:
18
Fields:
Hem
Hematology
Translation:
Humans
Cortes JE
, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G, Hochhaus A. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 08; 34(8):2064-2073.
PMID:
32265500
; PMCID:
PMC7387297
.
Citations:
5
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F,
Cortes JE
,
Daver N
,
Takahashi K
, Short NJ,
DiNardo CD
,
Jabbour E
,
Borthakur G
,
Naqvi K
, Issa GC,
Konopleva M
,
Khoury JD
,
Routbort M
, Pierce S,
Do KA
,
Bueso-Ramos C
, Patel K,
Kantarjian H
,
Garcia-Manero G
,
Kadia TM
. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
PMID:
32112433
.
Citations:
10
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Bose P
,
Verstovsek S
,
Cortes JE
, Tse S, Gasior Y,
Jain N
,
Jabbour EJ
,
Estrov Z
,
Alvarado Y
,
DiNardo CD
,
Pemmaraju N
,
Kornblau SM
,
Kadia TM
,
Daver NG
,
Naqvi K
, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X,
Garcia-Manero G
,
Kantarjian HM
, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
PMID:
32099037
.
Citations:
13
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Maiti A,
Cortes JE
,
Patel KP
, Masarova L,
Borthakur G
, Ravandi F,
Verstovsek S
,
Ferrajoli A
,
Estrov Z
,
Garcia-Manero G
,
Kadia TM
, Skinner J, Poku R, DellaSala S,
Luthra R
,
Jabbour EJ
, O'Brien S,
Kantarjian HM
, Nogueras-Gonz?lez GM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.
PMID:
31999839
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Masarova L,
Cortes JE
,
Patel KP
, O'Brien S, Nogueras-Gonzalez GM,
Konopleva M
,
Verstovsek S
,
Garcia-Manero G
,
Ferrajoli A
,
Kadia TM
,
Ravandi-Kashani F
,
Borthakur G
, DellaSala S,
Estrov Z
,
Jabbour EJ
,
Kantarjian HM
. Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.
PMID:
31999850
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Dao KT, Gotlib J, Deininger MMN, Oh ST,
Cortes JE
, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Savage S, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. J Clin Oncol. 2020 04 01; 38(10):1006-1018.
PMID:
31880950
; PMCID:
PMC7106977
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hughes TP, Mauro MJ,
Cortes JE
, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326.
PMID:
31826340
; PMCID:
PMC7724923
.
Citations:
54
Fields:
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Molica M,
Naqvi K
,
Cortes JE
, Paul S,
Kadia TM
, Breccia M,
Kantarjian H
,
Jabbour EJ
. Treatment-free remission in chronic myeloid leukemia. Clin Adv Hematol Oncol. 2019 Dec; 17(12):686-696.
PMID:
31851157
.
Citations:
2
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Kolitz JE, Strickland SA,
Cortes JE
, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 03; 61(3):631-640.
PMID:
31760835
.
Citations:
4
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Perl AE, Martinelli G,
Cortes JE
, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
PMID:
31665578
.
Citations:
246
Fields:
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Abou Dalle I,
Kantarjian HM
, Short NJ,
Konopleva M
,
Jain N
,
Garcia-Manero G
, Garris R, Qiao W,
Cortes JE
, O'Brien S,
Kebriaei P
,
Kadia T
,
Jabbour E
, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019 12; 94(12):1388-1395.
PMID:
31595534
.
Citations:
7
Fields:
Hem
Hematology
Translation:
Humans
Cells
Cortes JE
, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA, Dombret H, Merchant A. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019 Nov; 15(31):3531-3545.
PMID:
31516032
.
Citations:
22
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ravandi F, Assi R,
Daver N
,
Benton CB
,
Kadia T
, Thompson PA,
Borthakur G
,
Alvarado Y
,
Jabbour EJ
,
Konopleva M
,
Takahashi K
,
Kornblau S
,
DiNardo CD
,
Estrov Z
, Flores W, Basu S,
Allison J
,
Sharma P
, Pierce S, Pike A,
Cortes JE
,
Garcia-Manero G
,
Kantarjian HM
. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
PMID:
31400961
; PMCID:
PMC6778960
.
Citations:
31
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Gong Z, Xu ML, Chen M, Cui W,
Kantarjian HM
,
Cortes JE
, Zhou T, Tang G, Wang W,
Medeiros LJ
, Hu S. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia. Am J Hematol. 2019 10; 94(10):E256-E259.
PMID:
31273842
.
Citations:
Fields:
Hem
Hematology
Translation:
Humans
Cells
Sasaki K,
Kantarjian HM
,
Kadia T
, Patel K,
Loghavi S
,
Garcia-Manero G
,
Jabbour EJ
,
DiNardo C
,
Pemmaraju N
,
Daver N
, Dalle IA, Short N, Yilmaz M,
Bose P
,
Naqvi K
, Pierce S, Yalniz F,
Cortes JE
, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019 Nov 01; 125(21):3755-3766.
PMID:
31310323
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Shih YT
,
Cortes JE
,
Kantarjian HM
. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408.
PMID:
31208943
; PMCID:
PMC6658341
.
Citations:
14
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cortes JE
, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Hogge D, Jonas BA, Leung AY, Mehta P, Radsak M, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ, Kr?mer A, Dombret H, Montesinos P, Sica S. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 07; 20(7):984-997.
PMID:
31175001
.
Citations:
112
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Adrianza AM,
Jimenez CA
, Aldana GL, Pozo L,
Cortes JE
, Sagar AES. Tyrosine Kinase Inhibitor-associated Fibrothorax. Am J Respir Crit Care Med. 2019 06 01; 199(11):1432.
PMID:
30785770
; PMCID:
PMC6543723
.
Citations:
Fields:
Cri
Critical Care
Pul
Pulmonary Medicine
Translation:
Humans
Cortes JE
, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Curr Med Res Opin. 2019 09; 35(9):1615-1622.
PMID:
30964361
.
Citations:
4
Fields:
Med
Medicine (General)
Translation:
Humans
Cortes JE
, Jonas BA, Graef T, Luan Y, Stein AS. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):509-515.e1.
PMID:
31227358
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Gutzmer R, Kieran MW, Solomon JA. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019 Jun; 76:41-50.
PMID:
31125907
.
Citations:
39
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Animals
Cells
George GC
, Barata PC, Campbell A, Chen A,
Cortes JE
, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA,
Cleeland CS
,
Hong DS
. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019 Jun; 76:33-40.
PMID:
31108240
.
Citations:
8
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Cortes JE
, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, Crescenzo R, Mamolo C, Reisman A, BFORE Study Investigators, le Coutre P, Garcia-Gutierrez V, Hochhaus A, Br?mmendorf TH. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1589-1599.
PMID:
30989330
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Jain P,
Kantarjian H
, Boddu PC,
Verstovsek S
,
Garcia-Manero G
,
Borthakur G
, Sasaki K,
Kadia TM
, Sam P, Ahaneku H, O'Brien S,
Estrov Z
, Ravandi F,
Jabbour E
,
Cortes JE
, Nogueras-Gonz?lez GM. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 03 26; 3(6):851-861.
PMID:
30885996
; PMCID:
PMC6436011
.
Citations:
29
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Sasaki K,
Kantarjian HM
, O'Brien S, Ravandi F,
Konopleva M
,
Borthakur G
,
Garcia-Manero G
,
Wierda WG
,
Daver N
,
Ferrajoli A
,
Takahashi K
, Jain P, Rios MB, Pierce SA,
Jabbour EJ
,
Cortes JE
. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552.
PMID:
30830579
.
Citations:
13
Fields:
Hem
Hematology
Translation:
Humans
Abou Dalle I, Bannon SA,
Patel KP
,
Routbort MJ
,
Cortes JE
,
Ferrajoli A
,
Kontoyiannis DP
, Wang SA,
DiNardo CD
. Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol. 2019; 3.
PMID:
32914014
; PMCID:
PMC7446369
.
Citations:
1
Fields:
Neo
Neoplasms
Cortes JE
, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018 12 27; 11(1):143.
PMID:
30587215
; PMCID:
PMC6307238
.
Citations:
14
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cortes JE
. A second-generation TKI should always be used as initial therapy for CML. Blood Adv. 2018 12 26; 2(24):3653-3655.
PMID:
30587494
; PMCID:
PMC6306878
.
Citations:
4
Fields:
Hem
Hematology
Translation:
Humans
Maiti A,
Naqvi K
,
Kadia TM
,
Borthakur G
,
Takahashi K
,
Bose P
,
Daver NG
, Patel A,
Alvarado Y
,
Ohanian M
,
DiNardo CD
,
Cortes JE
,
Jabbour EJ
,
Garcia-Manero G
,
Kantarjian HM
, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1.
PMID:
30635233
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Pollyea DA, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M, Montesinos P, DesJardins P. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389.
PMID:
30555165
; PMCID:
PMC6365492
.
Citations:
158
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Williams P, Basu S,
Garcia-Manero G
, Hourigan CS, Oetjen KA,
Cortes JE
, Ravandi F,
Jabbour EJ
, Al-Hamal Z,
Konopleva M
,
Ning J
, Xiao L, Hidalgo Lopez J,
Kornblau SM
,
Andreeff M
, Flores W,
Bueso-Ramos C
, Blando J, Galera P, Calvo KR,
Al-Atrash G
,
Allison JP
,
Kantarjian HM
,
Sharma P
,
Daver NG
. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
PMID:
30500073
; PMCID:
PMC6467779
.
Citations:
84
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Daver N
,
Garcia-Manero G
, Basu S, Boddu PC, Alfayez M,
Cortes JE
,
Konopleva M
,
Ravandi-Kashani F
,
Jabbour E
,
Kadia T
, Nogueras-Gonzalez GM,
Ning J
,
Pemmaraju N
,
DiNardo CD
,
Andreeff M
, Pierce SA, Gordon T,
Kornblau SM
, Flores W, Alhamal Z,
Bueso-Ramos C
,
Jorgensen JL
,
Patel KP
, Blando J,
Allison JP
,
Sharma P
,
Kantarjian H
. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
PMID:
30409776
; PMCID:
PMC6397669
.
Citations:
151
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL, Hehlmann R, Michallet M. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 01; 94(1):46-54.
PMID:
30290003
; PMCID:
PMC6587733
.
Citations:
9
Fields:
Hem
Hematology
Translation:
Humans
Zulbaran-Rojas A, Lin HK,
Shi Q
,
Williams LA
, George B,
Garcia-Manero G
,
Jabbour E
, O'Brien S, Ravandi F,
Wierda W
,
Estrov Z
,
Borthakur G
,
Kadia T
,
Cleeland C
,
Cortes JE
,
Kantarjian H
. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
PMID:
30318751
; PMCID:
PMC6246941
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Boddu P,
Borthakur G
, Koneru M, Huang X,
Naqvi K
,
Wierda W
,
Bose P
,
Jabbour E
,
Estrov Z
,
Burger J
,
Alvarado Y
, Deshmukh A, Patel A, Cavazos A, Han L,
Cortes JE
,
Kantarjian H
,
Andreeff M
,
Konopleva M
. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369.
PMID:
30319961
; PMCID:
PMC6167965
.
Citations:
10
Cortes JE
, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018 11; 93(11):1301-1310.
PMID:
30074259
; PMCID:
PMC6221102
.
Citations:
49
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Masarova L,
Verstovsek S
, Hidalgo-Lopez JE,
Pemmaraju N
,
Bose P
,
Estrov Z
,
Jabbour EJ
,
Ravandi-Kashani F
,
Takahashi K
,
Cortes JE
, Ning J,
Ohanian M
,
Alvarado Y
, Zhou L, Pierce S, Gergis R,
Patel KP
,
Luthra R
,
Kadia TM
,
DiNardo CD
,
Borthakur G
,
Bhalla K
,
Garcia-Manero G
,
Bueso-Ramos CE
,
Kantarjian HM
,
Daver N
. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
PMID:
30185431
; PMCID:
PMC6265645
.
Citations:
28
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF,
Kantarjian H
, Khoury HJ, Kim DW, Healey D, Strauss L,
Cortes JE
. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 09 03; 8(9):88.
PMID:
30190469
; PMCID:
PMC6127283
.
Citations:
7
Fields:
All
Allergy and Immunology
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Hughes TP, Laneuville P, Snyder DS, Shah NP, Paar D, Abruzzese E, Lipton JH,
Cortes JE
, Rousselot P, Rea D, Hochhaus A. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019 01; 104(1):93-101.
PMID:
30093398
; PMCID:
PMC6312029
.
Citations:
22
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Abou Dalle I,
Cortes JE
, Pinnamaneni P,
Lamothe B
, Diaz Duque A, Randhawa J,
Pemmaraju N
,
Jabbour E
,
Ferrajoli A
,
Wierda WG
,
Estrov Z
,
Konopleva M
, Ravandi F,
Alvarado Y
,
Borthakur G
,
Gandhi V
,
Kantarjian HM
. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
PMID:
30071517
.
Citations:
5
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Short NJ,
Rytting ME
,
Cortes JE
. Acute myeloid leukaemia. Lancet. 2018 08 18; 392(10147):593-606.
PMID:
30078459
; PMCID:
PMC10230947
.
Citations:
165
Fields:
Med
Medicine (General)
Translation:
Humans
Lancet JE, Uy GL,
Cortes JE
, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692.
PMID:
30024784
; PMCID:
PMC6127025
.
Citations:
214
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Takahashi K
, Wang F, Morita K, Yan Y,
Hu P
, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L,
Tippen S
, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J,
DiNardo CD
,
Jain N
, Ravandi F,
Cortes JE
,
Garcia-Manero G
,
Kornblau S
,
Andreeff M
,
Jabbour E
,
Bueso-Ramos C
, Takaori-Kondo A,
Konopleva M
, Patel K,
Kantarjian H
, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018 07 10; 9(1):2670.
PMID:
29991687
; PMCID:
PMC6039465
.
Citations:
26
Fields:
Bio
Biology
Sci
Science
Translation:
Humans
Cells
Cortes JE
, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G,
Kantarjian HM
, Levis MJ. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 08 09; 132(6):598-607.
PMID:
29875101
; PMCID:
PMC6085992
.
Citations:
55
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Cortes J
, Perl AE,
Kantarjian H
, Martinelli G, Kovacsovics T, Estey E, Strickland S, Altman JK, Burnett A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M, D?hner H, Rousselot P, Steffen B, Dombret H, Baldus CD, Kr?mer A. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 07; 19(7):889-903.
PMID:
29859851
; PMCID:
PMC8152787
.
Citations:
101
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ,
Jabbour E
, Horst HA, Klimek VM,
Cortes JE
, Carella AM, Egyed M, Fox JA, Craig AR, Ward R, Smith JA, Acton G,
Kantarjian HM
, Stuart RK, Pigneux A, R?cher C, Krug U. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
PMID:
29794146
; PMCID:
PMC6278965
.
Citations:
2
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Gambacorti-Passerini C,
Cortes JE
, Lipton JH,
Kantarjian HM
, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Khoury HJ, Br?mmendorf TH. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica. 2018 08; 103(8):1298-1307.
PMID:
29773593
; PMCID:
PMC6068045
.
Citations:
15
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Ohanian M
, Rozovski U, Kanagal-Shamanna R, Abruzzo LV,
Loghavi S
,
Kadia T
,
Futreal A
,
Bhalla K
,
Zuo Z
,
Huh YO
,
Post SM
,
Ruvolo P
,
Garcia-Manero G
,
Andreeff M
,
Kornblau S
,
Borthakur G
,
Hu P
,
Medeiros LJ
,
Takahashi K
, Hornbaker MJ, Zhang J, Huang X,
Verstovsek S
,
Estrov Z
, Pierce S, Ravandi F,
Kantarjian HM
,
Bueso-Ramos CE
,
Cortes JE
, Nogueras-Gonz?lez GM. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
PMID:
29741984
; PMCID:
PMC6226369
.
Citations:
27
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Morita K,
Kantarjian HM
, Wang F, Yan Y,
Bueso-Ramos C
, Sasaki K, Issa GC, Wang S,
Jorgensen J
, Song X, Zhang J,
Tippen S
, Thornton R, Coyle M, Little L, Gumbs C,
Pemmaraju N
,
Daver N
,
DiNardo CD
,
Konopleva M
,
Andreeff M
, Ravandi F,
Cortes JE
,
Kadia T
,
Jabbour E
,
Garcia-Manero G
,
Patel KP
, Futreal PA,
Takahashi K
. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.
PMID:
29702001
; PMCID:
PMC6008108
.
Citations:
66
Fields:
Neo
Neoplasms
Translation:
Humans
Assi R,
Kantarjian HM
,
Kadia TM
,
Pemmaraju N
,
Jabbour E
,
Jain N
,
Daver N
,
Estrov Z
, Uehara T, Owa T,
Cortes JE
,
Borthakur G
. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
PMID:
29660836
; PMCID:
PMC6800041
.
Citations:
28
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Kantarjian HM
,
DiNardo CD
, Nogueras-Gonzalez GM,
Kadia TM
,
Jabbour E
,
Bueso-Ramos CE
, O'Brien SM,
Konopleva M
,
Jain NB
,
Daver NG
,
Shpall EJ
,
Champlin RE
, Simkins A,
Garcia-Manero G
, Keating MJ, Huang X,
Cortes JE
, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
PMID:
29645075
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Cortes JE
, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Gambacorti-Passerini C, Lustgarten S,
Rivera VM
, Haluska FG, Deininger MW, Hochhaus A, Hughes TP, Shah NP,
Kantarjian HM
, le Coutre PD, Nicolini FE, Rea D, M?ller MC, Guilhot F. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
PMID:
29567798
; PMCID:
PMC6071555
.
Citations:
119
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J,
Kantarjian HM
, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G,
Cortes JE
. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303.
PMID:
29463550
.
Citations:
49
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Naqvi K
,
Cortes JE
, Luthra R, O'Brien S,
Wierda W
,
Borthakur G
,
Kadia T
,
Garcia-Manero G
, Ravandi F, Rios MB, Dellasala S, Pierce S,
Jabbour E
, Patel K,
Kantarjian H
. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol. 2018 Jun; 107(6):689-695.
PMID:
29464484
.
Citations:
3
Fields:
Hem
Hematology
Translation:
Humans
Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ,
Cortes JE
, Barbui T, Mauro M, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O, Hehlmann R, Saussele S. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018 04; 67:67-74.
PMID:
29466766
; PMCID:
PMC6613209
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Sasaki K,
Kantarjian H
, O'Brien S, Ravandi F,
Konopleva M
,
Borthakur G
,
Garcia-Manero G
,
Wierda W
,
Daver N
,
Ferrajoli A
,
Takahashi K
, Jain P, Rios MB, Pierce S,
Jabbour E
,
Cortes JE
. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
PMID:
29266206
; PMCID:
PMC5851790
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Gong Z, Medeiros LJ,
Cortes JE
, Chen Z, Zheng L, Li Y, Bai S, Lin P,
Miranda RN
,
Jorgensen JL
,
McDonnell TJ
, Wang W,
Kantarjian HM
, Hu S. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017 Dec 12; 1(26):2541-2552.
PMID:
29296906
; PMCID:
PMC5728641
.
Citations:
13
Fields:
Hem
Hematology
Altman JK, Foran JM, Pratz KW, Trone D,
Cortes JE
, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):213-221.
PMID:
29139135
; PMCID:
PMC6586071
.
Citations:
34
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Assi R,
Kantarjian HM
,
Garcia-Manero G
,
Cortes JE
,
Pemmaraju N
, Wang X, Nogueras-Gonzalez G,
Jabbour E
,
Bose P
,
Kadia T
,
Dinardo CD
, Patel K,
Bueso-Ramos C
, Zhou L, Pierce S, Gergis R, Tuttle C,
Borthakur G
,
Estrov Z
,
Luthra R
, Hidalgo-Lopez J,
Verstovsek S
,
Daver N
. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
PMID:
29134664
.
Citations:
18
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Masarova L, Yin CC,
Cortes JE
,
Konopleva M
,
Borthakur G
, Newberry KJ,
Kantarjian HM
,
Bueso-Ramos CE
,
Verstovsek S
. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017; 6:30.
PMID:
29152412
; PMCID:
PMC5679503
.
Citations:
11
Cortes JE
, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Br?mmendorf TH. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018 01 20; 36(3):231-237.
PMID:
29091516
; PMCID:
PMC5966023
.
Citations:
114
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Kantarjian HM
, Mamolo CM, Gambacorti-Passerini C,
Cortes JE
, Su Y, Reisman AL, Shapiro M, Lipton JH, Br?mmendorf TH. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018 02 01; 124(3):587-595.
PMID:
29072772
; PMCID:
PMC5813200
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Goldberg SL,
Cortes JE
, Gambacorti-Passerini C, Khoury HJ, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Lomaia E, Olavarria E, Mauro MJ, Hehlmann R, Michallet M, Hansen R. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Nov; 92(11):1214-1223.
PMID:
28815757
; PMCID:
PMC5659133
.
Citations:
9
Fields:
Hem
Hematology
Translation:
Humans
Issa GC,
Kantarjian HM
, Gonzalez GN,
Borthakur G
, Tang G,
Wierda W
, Sasaki K, Short NJ, Ravandi F,
Kadia T
, Patel K, Luthra R,
Ferrajoli A
,
Garcia-Manero G
, Rios MB, Dellasala S,
Jabbour E
,
Cortes JE
. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017 11 09; 130(19):2084-2091.
PMID:
28835440
; PMCID:
PMC5680612
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Jain P,
Kantarjian HM
, Ghorab A, Sasaki K,
Jabbour EJ
, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC,
Garcia-Manero G
, Kc D, Dellasala S, Pierce S,
Konopleva M
,
Wierda WG
,
Verstovsek S
,
Daver NG
,
Kadia TM
,
Borthakur G
, O'Brien S,
Estrov Z
, Ravandi F,
Cortes JE
. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
PMID:
28743165
; PMCID:
PMC5673547
.
Citations:
47
Fields:
Neo
Neoplasms
Translation:
Humans
Boddu P,
Kantarjian HM
,
Garcia-Manero G
, Ravandi F,
Verstovsek S
,
Jabbour E
,
Borthakur G
,
Konopleva M
,
Bhalla KN
,
Daver N
,
DiNardo CD
,
Benton CB
,
Takahashi K
,
Estrov Z
, Pierce SR,
Andreeff M
,
Cortes JE
,
Kadia TM
. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323.
PMID:
29296774
; PMCID:
PMC5727976
.
Citations:
26
Fields:
Hem
Hematology
Short NJ,
Kantarjian H
, Ravandi F, Huang X, Xiao L,
Garcia-Manero G
, Plunkett W,
Gandhi V
, Sasaki K,
Pemmaraju N
,
Daver NG
,
Borthakur G
,
Jain N
,
Konopleva M
,
Estrov Z
,
Kadia TM
,
Wierda WG
,
DiNardo CD
, Brandt M, O'Brien SM,
Cortes JE
,
Jabbour E
. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
PMID:
28718728
; PMCID:
PMC5773400
.
Citations:
7
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Jabbour E
, Short NJ, Ravandi F, Huang X, Xiao L,
Garcia-Manero G
, Plunkett W,
Gandhi V
, Sasaki K,
Pemmaraju N
,
Daver NG
,
Borthakur G
,
Jain N
,
Konopleva M
,
Estrov Z
,
Kadia TM
,
Wierda WG
,
DiNardo CD
, Brandt M, O'Brien SM,
Cortes JE
,
Kantarjian H
. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
PMID:
28708931
; PMCID:
PMC5739034
.
Citations:
15
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Gambacorti-Passerini C, Kim DW,
Kantarjian HM
, Lipton JH,
Lahoti A
, Talpaz M, Matczak E, Barry E, Leip E, Khoury HJ, Br?mmendorf TH. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):684-695.e6.
PMID:
28807791
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Short NJ,
Kantarjian H
,
Jabbour E
,
Cortes JE
, Thomas DA,
Rytting ME
,
Daver N
,
Alvarado Y
,
Konopleva M
,
Kebriaei P
,
Wierda WG
,
DiNardo CD
, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444.
PMID:
28616864
; PMCID:
PMC6511975
.
Citations:
5
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW,
Cortes JE
, Watts JM, Yarranton GT, Walling JM, Lancet JE. Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]. Leuk Res. 2017 08; 59:65.
PMID:
28575698
.
Citations:
1
Fields:
Neo
Neoplasms
Masarova L, Todisco G, Manshouri T, Newberry KJ,
Cortes JE
,
Kantarjian HM
,
Estrov Z
,
Verstovsek S
. Therapy-related myelofibrosis does not appear to exist. Blood Adv. 2017 Jun 13; 1(14):863-866.
PMID:
29296729
; PMCID:
PMC5737601
.
Citations:
1
Fields:
Hem
Hematology
Short NJ,
Kantarjian HM
, Ko H,
Khoury JD
, Ravandi F, Thomas DA,
Garcia-Manero G
, Khouri M,
Cortes JE
,
Wierda WG
,
Verstovsek S
,
Estrov Z
,
Ferrajoli A
, Thompson PA, Pierce S, O'Brien SM,
Jabbour E
. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
PMID:
28295472
; PMCID:
PMC5828013
.
Citations:
7
Fields:
Hem
Hematology
Translation:
Humans
Boddu PC,
Kantarjian HM
, Ravandi F,
Garcia-Manero G
,
Verstovsek S
,
Jabbour EJ
,
Takahashi K
,
Bhalla K
,
Konopleva M
,
DiNardo CD
,
Ohanian M
,
Pemmaraju N
,
Jain N
, Pierce S,
Wierda WG
,
Cortes JE
,
Kadia TM
. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060.
PMID:
28387922
; PMCID:
PMC5544569
.
Citations:
15
Fields:
Neo
Neoplasms
Translation:
Humans
Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ,
Kantarjian HM
,
Cortes JE
, Nicolini FE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Aug 01; 123(15):2875-2880.
PMID:
28387926
; PMCID:
PMC5573914
.
Citations:
30
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Jain N
,
Balakrishnan K
,
Ferrajoli A
, O'Brien SM,
Burger JA
,
Kadia TM
,
Cortes JE
, Ayres ML, Tambaro FP, Keating MJ,
Gandhi V
,
Wierda WG
. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
PMID:
27655665
; PMCID:
PMC5400650
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Bose P
, Vachhani P,
Cortes JE
. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17.
PMID:
28286924
.
Citations:
82
Fields:
Neo
Neoplasms
Translation:
Humans
Short NJ,
Kantarjian HM
, Sasaki K, Ravandi F, Ko H, Cameron Yin C,
Garcia-Manero G
,
Cortes JE
, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D,
Jain N
,
Kadia TM
,
Daver NG
,
Benton CB
, Issa GC,
Konopleva M
,
Jabbour E
. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243.
PMID:
28006851
; PMCID:
PMC5495018
.
Citations:
12
Fields:
Hem
Hematology
Translation:
Humans
Cells
Cortes J
, Talpaz M, Smith HP, Snyder DS, Khoury J,
Bhalla KN
, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL,
Kantarjian HM
, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528.
PMID:
27927766
; PMCID:
PMC5394958
.
Citations:
9
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
DiNardo CD
,
Cortes JE
. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):348-355.
PMID:
27913501
; PMCID:
PMC6142505
.
Citations:
44
Fields:
Hem
Hematology
Translation:
Humans
Cortes JE
, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, Huang X, Babu KG, Abdulkadyrov K, Shen ZX, Liang Z, Owugah T, Szczudlo T, Khanna S, Fellague-Chebra R, de Oliveira JSR, Sacha T, Bendit I, le Coutre PD. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591.
PMID:
27890073
.
Citations:
13
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Cortes JE
, Hochhaus A. Reply to K.R. Hoffman. J Clin Oncol. 2017 02 10; 35(5):567-568.
PMID:
29236618
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Koller PB,
Kantarjian HM
, Nogueras-Gonzalez GM,
Jabbour E
,
Verstovsek S
,
Borthakur G
,
Estrov Z
,
Wierda WG
,
Garcia-Manero G
,
Ferrajoli A
, Ravandi F, O'Brien SM,
Cortes JE
. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
PMID:
27763690
; PMCID:
PMC5293656
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Issa GC,
Kantarjian HM
, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K,
Garcia-Manero G
,
Kadia TM
,
Cortes JE
,
Daver N
,
Borthakur G
,
Jain N
,
Konopleva M
,
Khouri I
,
Kebriaei P
,
Champlin RE
, Pierce S, O'Brien SM,
Jabbour E
. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
PMID:
27696391
; PMCID:
PMC5321542
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW,
Cortes JE
, Watts JM, Yarranton GT, Walling JM, Lancet JE. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016 11; 50:123-131.
PMID:
27736729
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Maiti A,
Cortes JE
, Brown YD,
Kantarjian HM
. Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors. Leuk Lymphoma. 2017 03; 58(3):722-725.
PMID:
27658536
; PMCID:
PMC5250544
.
Citations:
1
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
,
Jimenez CA
, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. Clin Lymphoma Myeloma Leuk. 2017 02; 17(2):78-82.
PMID:
28082112
.
Citations:
30
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes JE
, Khoury HJ,
Kantarjian HM
, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Gambacorti-Passerini C, Br?mmendorf TH. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 12; 91(12):1206-1214.
PMID:
27531525
; PMCID:
PMC5303616
.
Citations:
23
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Jabbour E
, Short NJ,
Jorgensen JL
, Yilmaz M, Ravandi F, Wang SA, Thomas DA,
Khoury J
,
Champlin RE
,
Khouri I
,
Kebriaei P
, O'Brien SM,
Garcia-Manero G
,
Cortes JE
, Sasaki K,
Dinardo CD
,
Kadia TM
,
Jain N
,
Konopleva M
, Garris R,
Kantarjian HM
. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
PMID:
27602508
; PMCID:
PMC5321541
.
Citations:
29
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Short NJ,
Kantarjian HM
, Sasaki K,
Cortes JE
, Ravandi F, Thomas DA,
Garcia-Manero G
,
Khouri I
,
Kebriaei P
,
Champlin RE
, Pierce S, Issa GC,
Konopleva M
,
Kadia TM
,
Bueso-Ramos C
,
Khoury JD
,
Jain N
, O'Brien SM,
Jabbour E
. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
PMID:
27508525
; PMCID:
PMC5321530
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Takahashi K
,
Kantarjian HM
, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F,
Kadia T
,
Pemmaraju N
,
Daver N
,
Borthakur G
,
Garcia-Manero G
,
Jabbour E
,
Cortes JE
. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343.
PMID:
27509035
; PMCID:
PMC5073019
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hoehn D,
Cortes JE
, Medeiros LJ,
Jabbour EJ
, Hidalgo JE, Kanagal-Shamanna R,
Bueso-Ramos CE
. Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S86-92.
PMID:
27521332
; PMCID:
PMC5843379
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Sasaki K,
Jabbour EJ
, Ravandi F, Short NJ, Thomas DA,
Garcia-Manero G
,
Daver NG
,
Kadia TM
,
Konopleva MY
,
Jain N
, Issa GC, Jeanis V, Moore HG, Garris RS,
Pemmaraju N
,
Cortes JE
, O'Brien SM,
Kantarjian HM
. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656.
PMID:
27479888
; PMCID:
PMC5321539
.
Citations:
51
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Dorer DJ, Knickerbocker RK, Baccarani M,
Cortes JE
, Hochhaus A, Talpaz M, Haluska FG. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 09; 48:84-91.
PMID:
27505637
.
Citations:
45
Fields:
Neo
Neoplasms
Translation:
Humans
Rytting ME
,
Jabbour EJ
,
Jorgensen JL
, Ravandi F, Franklin AR,
Kadia TM
,
Pemmaraju N
,
Daver NG
,
Ferrajoli A
,
Garcia-Manero G
,
Konopleva MY
,
Borthakur G
, Garris R, Wang S, Pierce S, Schroeder K,
Kornblau SM
, Thomas DA,
Cortes JE
, O'Brien SM,
Kantarjian HM
. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
PMID:
27178680
; PMCID:
PMC5558853
.
Citations:
36
Fields:
Hem
Hematology
Translation:
Humans
Cells
Badar T, Handisides DR, Benito JM, Richie MA,
Borthakur G
,
Jabbour E
, Harutyunyan K,
Konoplev S
, Faderl S, Kroll S,
Andreeff M
, Pearce T,
Kantarjian HM
,
Cortes JE
, Thomas DA,
Konopleva M
. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. Am J Hematol. 2016 08; 91(8):800-5.
PMID:
27169385
; PMCID:
PMC4946992
.
Citations:
16
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Shah NP, Schiffer C, Rea D,
Cortes JE
, Milone J,
Mohamed H
, Healey D,
Kantarjian H
, Saglio G, Rousselot P, Hochhaus A. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74.
PMID:
27192969
; PMCID:
PMC5094534
.
Citations:
53
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Tamamyan GN,
Kantarjian HM
,
Ning J
, Jain P, Sasaki K, McClain KL,
Allen CE
, Pierce SA,
Cortes JE
, Ravandi F,
Konopleva MY
,
Garcia-Manero G
,
Benton CB
, Chihara D,
Rytting ME
, Wang S, Abdelall W,
Konoplev SN
,
Daver NG
. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66.
PMID:
27244347
; PMCID:
PMC5014667
.
Citations:
30
Fields:
Neo
Neoplasms
Translation:
Humans
Short NJ,
Jabbour E
, Sasaki K, Patel K, O'Brien SM,
Cortes JE
, Garris R, Issa GC,
Garcia-Manero G
,
Luthra R
, Thomas D,
Kantarjian H
, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 07 28; 128(4):504-7.
PMID:
27235138
; PMCID:
PMC4965905
.
Citations:
63
Fields:
Hem
Hematology
Translation:
Humans
Cells
Cortes JE
, Saglio G,
Kantarjian HM
, Baccarani M, Mayer J, Boqu? C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na?ve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 07 10; 34(20):2333-40.
PMID:
27217448
; PMCID:
PMC5118045
.
Citations:
243
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Sasaki K,
Kantarjian H
,
Jabbour E
, Ravandi F,
Takahashi K
,
Konopleva M
,
Borthakur G
,
Garcia-Manero G
,
Wierda W
,
Daver N
, Jain P, Satta T, Pierce S, Rios MB,
Cortes JE
. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7.
PMID:
27175025
; PMCID:
PMC4967581
.
Citations:
2
Fields:
Hem
Hematology
Translation:
Humans
Whiteley J, Reisman A, Shapiro M,
Cortes J
, Cella D. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016 08; 32(8):1325-34.
PMID:
27045164
.
Citations:
12
Fields:
Med
Medicine (General)
Translation:
Humans
Cortes JE
, Jean Khoury H,
Kantarjian H
, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C, Br?mmendorf TH. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016 06; 91(6):606-16.
PMID:
26971533
; PMCID:
PMC5548463
.
Citations:
33
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Lipton JH, Chuah C, Rosti G, Simpson D, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S,
Rivera VM
, Clackson T, Haluska FG, Baccarani M,
Cortes JE
, Hughes T,
Kantarjian HM
, Shah NP, Talpaz M, Deininger MW, EPIC investigators, Guerci-Bresler A, Assouline S, Etienne G, Nicolini FE, le Coutre P, Guilhot F, Hochhaus A. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
PMID:
27083332
.
Citations:
79
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Chen LS, Yang JY,
Liang H
,
Cortes JE
,
Gandhi V
. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873.
PMID:
27054578
; PMCID:
PMC5650058
.
Citations:
9
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Wang W,
Cortes JE
, Tang G,
Khoury JD
, Wang S,
Bueso-Ramos CE
, DiGiuseppe JA, Chen Z,
Kantarjian HM
, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 06 02; 127(22):2742-50.
PMID:
27006386
; PMCID:
PMC4915795
.
Citations:
45
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Schiffer CA,
Cortes JE
, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S,
Mohamed H
, Shah NP. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407.
PMID:
26998677
; PMCID:
PMC5071708
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Cortes JE
, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk. 2016 05; 16(5):286-96.
PMID:
26993758
; PMCID:
PMC4965237
.
Citations:
14
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Short NJ,
Kantarjian HM
,
Jabbour EJ
, O'Brien SM, Faderl S,
Burger JA
, Garris R, Qiao W, Huang X,
Jain N
,
Konopleva M
,
Kadia TM
,
Daver N
,
Borthakur G
,
Cortes JE
, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9.
PMID:
26800008
; PMCID:
PMC5834229
.
Citations:
Fields:
Hem
Hematology
Translation:
Humans
Benito J, Ramirez MS,
Millward NZ
, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P,
Jacamo R
, Ma H,
Konoplev S
, McQueen T, Volgin A, Protopopova M, Mu H, Lee J,
Bhattacharya PK
, Marszalek JR, Davis RE,
Bankson JA
,
Cortes JE
, Hart CP,
Andreeff M
,
Konopleva M
. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98.
PMID:
26603259
; PMCID:
PMC4818660
.
Citations:
35
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Deininger MW, Hodgson JG, Shah NP,
Cortes JE
, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F,
Kantarjian HM
, Soverini S, Hughes TP,
Rivera VM
, Branford S, M?ller MC, Hochhaus A. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12.
PMID:
26603839
; PMCID:
PMC4760131
.
Citations:
27
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Khoury HJ,
Kantarjian HM
, Kim DW, Schafhausen P, Conlan MG, Shapiro M, Turnbull K, Leip E, Gambacorti-Passerini C, Lipton JH, Br?mmendorf TH. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016 Jan; 172(1):97-110.
PMID:
26537529
; PMCID:
PMC4737299
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Ravandi F,
Jorgensen JL
, O'Brien SM,
Jabbour E
, Thomas DA,
Borthakur G
, Garris R, Huang X,
Garcia-Manero G
,
Burger JA
,
Ferrajoli A
,
Wierda W
,
Kadia T
,
Jain N
, Wang SA, Konoplev S,
Kebriaei P
,
Champlin RE
, McCue D,
Estrov Z
,
Cortes JE
,
Kantarjian HM
. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.
PMID:
26492205
; PMCID:
PMC4826052
.
Citations:
38
Fields:
Hem
Hematology
Translation:
Humans
Sasaki K,
Kantarjian HM
, Jain P,
Jabbour EJ
, Ravandi F,
Konopleva M
,
Borthakur G
,
Takahashi K
,
Pemmaraju N
,
Daver N
, Pierce SA, O'Brien SM,
Cortes JE
. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48.
PMID:
26479889
; PMCID:
PMC4707980
.
Citations:
16
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes JE
, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015 Dec; 90(12):1111-5.
PMID:
26348106
; PMCID:
PMC5115878
.
Citations:
36
Fields:
Hem
Hematology
Translation:
Humans
Thompson PA
,
Kantarjian HM
,
Cortes JE
. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc. 2015 Oct; 90(10):1440-54.
PMID:
26434969
; PMCID:
PMC5656269
.
Citations:
23
Fields:
Med
Medicine (General)
Translation:
Humans
Cells
Masarova L, Cherry M, Newberry KJ,
Estrov Z
,
Cortes JE
,
Kantarjian HM
,
Verstovsek S
. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016; 57(1):237-9.
PMID:
25904378
; PMCID:
PMC4712116
.
Citations:
14
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Badar T,
Kantarjian HM
, Nogueras-Gonzalez GM,
Borthakur G
, Garcia Manero G,
Andreeff M
,
Konopleva M
,
Kadia TM
,
Daver N
,
Wierda WG
, Luthra R, Patel K,
Oran B
,
Champlin R
, Ravandi F,
Cortes JE
. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70.
PMID:
26299958
; PMCID:
PMC4618182
.
Citations:
10
Fields:
Hem
Hematology
Translation:
Humans
Ravandi F, O'Brien SM,
Cortes JE
, Thomas DM, Garris R, Faderl S,
Burger JA
,
Rytting ME
,
Ferrajoli A
,
Wierda WG
,
Verstovsek S
,
Champlin R
,
Kebriaei P
, McCue DA, Huang X,
Jabbour E
,
Garcia-Manero G
,
Estrov Z
,
Kantarjian HM
. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.
PMID:
26308885
; PMCID:
PMC4666803
.
Citations:
61
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Wang W,
Cortes JE
, Lin P, Beaty MW, Ai D,
Amin HM
,
McDonnell TJ
,
Ok CY
,
Kantarjian HM
, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015 Oct 01; 126(14):1699-706.
PMID:
26243778
; PMCID:
PMC4624442
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
Cells
Pardanani A, Harrison C,
Cortes JE
, Cervantes F, Mesa RA, Milligan D, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A, Masszi T. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1(5):643-51.
PMID:
26181658
.
Citations:
141
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ,
Jabbour E
, Erba HP, Horst HA, Klimek VM,
Cortes J
, Roboz GJ, Odenike O, Havelange V, Maertens J, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK,
Kantarjian HM
, Pigneux A, Recher C, Thomas X, Derigs HG. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
PMID:
26234174
; PMCID:
PMC4822512
.
Citations:
55
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Yilmaz M,
Lahoti A
, O'Brien S,
Burger J
,
Ferrajoli A
,
Borthakur G
, Ravandi F, Pierce S,
Jabbour E
,
Kantarjian H
,
Cortes JE
, Nogueras-Gonz?lez GM. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015 Nov 01; 121(21):3894-904.
PMID:
26217876
; PMCID:
PMC4519988
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
Badar T, Shetty A,
Bueso-Ramos C
,
Cortes J
,
Konopleva M
,
Borthakur G
, Pierce S,
Huang X
, Chen HC,
Kadia T
,
Daver N
,
Dinardo C
, O'Brien S,
Garcia-Manero G
,
Kantarjian H
, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73.
PMID:
26017166
; PMCID:
PMC4546505
.
Citations:
11
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik MN, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J, Baccarani M,
Kantarjian HM
, Levin WJ,
Cortes JE
, Jamieson C. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015 Aug; 2(8):e339-46.
PMID:
26688487
.
Citations:
56
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F,
Kantarjian H
,
Cortes JE
. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7.
PMID:
26205361
; PMCID:
PMC4770883
.
Citations:
11
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Tefferi A,
Kantarjian H
, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH,
Allison J
, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G,
Cortes J
, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M,
Mendelsohn J
, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R,
Strong LC
, Tallman MS, Thompson M,
Ueno NT
, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
PMID:
26211600
; PMCID:
PMC5365030
.
Citations:
44
Fields:
Med
Medicine (General)
Translation:
Humans
Patel KP
, Newberry KJ,
Luthra R
,
Jabbour E
, Pierce S,
Cortes J
,
Singh R
, Mehrotra M,
Routbort MJ
, Luthra M, Manshouri T, Santos FP,
Kantarjian H
,
Verstovsek S
. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.
PMID:
26124496
; PMCID:
PMC4528066
.
Citations:
74
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Badar T,
Kantarjian HM
, Ravandi F,
Jabbour E
,
Borthakur G
,
Cortes JE
,
Pemmaraju N
, Pierce SR, Newberry KJ,
Daver N
,
Verstovsek S
. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6.
PMID:
26183878
; PMCID:
PMC4546869
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
Sanford D,
DiNardo CD
, Tang G,
Cortes JE
,
Verstovsek S
,
Jabbour E
, Ravandi F,
Kantarjian H
,
Garcia-Manero G
. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):556-62.
PMID:
26141213
; PMCID:
PMC4837956
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Hui D
, Bansal S, Park M,
Reddy A
,
Cortes J
,
Fossella F
,
Bruera E
. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol. 2015 Jul; 26(7):1440-6.
PMID:
26041765
; PMCID:
PMC4855240
.
Citations:
28
Fields:
Neo
Neoplasms
Translation:
Humans
Cho BS,
Zeng Z
, Mu H, Wang Z,
Konoplev S
, McQueen T, Protopopova M,
Cortes J
, Marszalek JR, Peng SB, Ma W,
Davis RE
, Thornton DE,
Andreeff M
,
Konopleva M
. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32.
PMID:
26031918
; PMCID:
PMC4497963
.
Citations:
52
Fields:
Hem
Hematology
Translation:
Humans
Animals
Cells
Gambacorti-Passerini C,
Kantarjian HM
, Kim DW, Khoury HJ, Turkina AG, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E,
Cortes JE
, Br?mmendorf TH. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep; 90(9):755-68.
PMID:
26040495
; PMCID:
PMC5132035
.
Citations:
26
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Loghavi S
,
Pemmaraju N
, Kanagal-Shamanna R, Mehrotra M,
Medeiros LJ
,
Luthra R
,
Lin P
,
Huh Y
,
Kantarjian HM
,
Cortes JE
,
Verstovsek S
,
Patel KP
. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3.
PMID:
25999449
.
Citations:
7
Fields:
Hem
Hematology
Translation:
Humans
Masarova L, Newberry KJ, Pierce SA,
Estrov Z
,
Cortes JE
,
Kantarjian HM
,
Verstovsek S
. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res. 2015 Aug; 39(8):822-7.
PMID:
26012362
; PMCID:
PMC4547830
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Sasaki K, Strom SS, O'Brien S,
Jabbour E
, Ravandi F,
Konopleva M
,
Borthakur G
,
Pemmaraju N
,
Daver N
, Jain P, Pierce S,
Kantarjian H
,
Cortes JE
. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93.
PMID:
26688093
; PMCID:
PMC4884053
.
Citations:
86
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Borthakur G
, Dombret H, Schafhausen P, Brummendorf TH, Boissel N,
Jabbour E
, Mariani M, Capolongo L, Carpinelli P, Davite C,
Kantarjian H
,
Cortes JE
. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica. 2015 Jul; 100(7):898-904.
PMID:
25887498
; PMCID:
PMC4486224
.
Citations:
22
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Wang W
, Tang G,
Cortes JE
, Liu H, Ai D, Yin CC, Li S,
Khoury JD
,
Bueso-Ramos C
,
Medeiros LJ
, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32.
PMID:
25888368
; PMCID:
PMC4396174
.
Citations:
12
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Karjalainen K, Jaalouk DE,
Bueso-Ramos C
,
Bover L
, Sun Y, Kuniyasu A, Driessen WH, Rietz C, Zurita AJ, O'Brien S,
Kantarjian HM
,
Cortes JE
,
Calin GA
, Koivunen E, Arap W, Pasqualini R, Card?-Vila M. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 01; 21(13):3041-51.
PMID:
25779950
; PMCID:
PMC4490100
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Sanford DS,
Kantarjian H
, O'Brien S,
Jabbour E
,
Cortes J
, Ravandi F. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2015 Apr; 15(4):365-73.
PMID:
25764322
.
Citations:
6
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Kadia T
,
Kantarjian H
,
Garcia-Manero G
,
Borthakur G
, Wang X, Patel K,
Jabbour E
, Brandt M,
Daver N
,
Pemmaraju N
, Pierce S,
Cortes J
, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.
PMID:
25716073
; PMCID:
PMC4977576
.
Citations:
5
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Badar T,
Cortes JE
, Ravandi F, O'Brien S,
Verstovsek S
,
Garcia-Manero G
,
Kantarjian H
,
Borthakur G
. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2.
PMID:
25795639
; PMCID:
PMC4509631
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F,
Cortes JE
, Kelly P, Kutok JL,
Kantarjian HM
,
Verstovsek S
. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015 Jul; 56(7):2092-7.
PMID:
25641433
; PMCID:
PMC4919663
.
Citations:
30
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cachia D, Kamiya-Matsuoka C,
Pinnix CC
, Chi L,
Kantarjian HM
,
Cortes JE
,
Daver N
,
Woodman K
. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015 Apr; 122(2):391-8.
PMID:
25666482
; PMCID:
PMC4369460
.
Citations:
13
Fields:
Neo
Neoplasms
Neu
Neurology
Translation:
Humans
CT
Clinical Trials
Badar T,
Cortes J
,
Borthakur G
, O'Brien S,
Wierda W
,
Garcia-Manero G
,
Ferrajoli A
,
Kadia T
, Poku R,
Kantarjian H
, Mattiuzzi G. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597.
PMID:
25654108
; PMCID:
PMC4310492
.
Citations:
5
Fields:
Bio
Biotechnology
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Cortes JE
,
Kantarjian HM
, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE, Guerci-Bresler A. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15; 121(10):1637-44.
PMID:
25586015
; PMCID:
PMC5650096
.
Citations:
25
Fields:
Neo
Neoplasms
Translation:
Humans
DiNardo CD
,
Daver N
,
Jabbour E
,
Kadia T
,
Borthakur G
,
Konopleva M
,
Pemmaraju N
, Yang H, Pierce S,
Wierda W
,
Bueso-Ramos C
,
Patel KP
,
Cortes JE
, Ravandi F,
Kantarjian HM
,
Garcia-Manero G
. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
PMID:
26687423
; PMCID:
PMC4936479
.
Citations:
6
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
DiNardo CD
,
Cortes JE
. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015 Jan; 16(1):95-106.
PMID:
25480777
.
Citations:
10
Fields:
Pha
Pharmacology
Translation:
Humans
Verstovsek S
, Hoffman R, Mascarenhas J, McCoon P, Tang W,
Cortes J
,
Kantarjian H
, Soria JC, Bahleda R, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. 2015 Feb; 39(2):157-63.
PMID:
25530567
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Kadia TM
,
Kantarjian HM
, Thomas DA, O'Brien S,
Estrov Z
, Ravandi F,
Jabbour E
,
Pemmaraju N
,
Daver N
, Wang X, Jain P, Pierce S, Brandt M,
Garcia-Manero G
,
Cortes J
,
Borthakur G
. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
PMID:
25368968
; PMCID:
PMC4447180
.
Citations:
6
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Issa JP,
Garcia-Manero G
,
Huang X
,
Cortes J
, Ravandi F,
Jabbour E
,
Borthakur G
, Brandt M, Pierce S,
Kantarjian HM
. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61.
PMID:
25336333
; PMCID:
PMC4320000
.
Citations:
53
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Pemmaraju N
,
Kantarjian H
,
Garcia-Manero G
, Pierce S, Cardenas-Turanzas M,
Cortes J
, Ravandi F. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015 Jan; 90(1):27-30.
PMID:
25251041
; PMCID:
PMC4276516
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
Daver N
,
Kantarjian H
, Marcucci G, Pierce S, Brandt M,
Dinardo C
,
Pemmaraju N
,
Garcia-Manero G
, O'Brien S,
Ferrajoli A
,
Verstovsek S
,
Popat U
,
Hosing C
,
Anderlini P
,
Borthakur G
,
Kadia T
,
Cortes J
, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
PMID:
25312977
; PMCID:
PMC4323735
.
Citations:
18
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Agarwal A, Mackenzie RJ, Jeng S, Carey A, LaTocha DH, Fleischman AG, Eide CA, Vasudevan KB, Loriaux MM, Firpo E,
Cortes JE
, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW, Besson A, Duquesnes N. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 2014 Nov 20; 124(22):3260-73.
PMID:
25293778
; PMCID:
PMC4239335
.
Citations:
14
Fields:
Hem
Hematology
Translation:
Humans
Animals
Cells
Kantarjian H
, O'Brien S,
Jabbour E
, Barnes G, Pathak A,
Cortes J
. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):13-21.
PMID:
25458084
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Loghavi S
,
Zuo Z
, Ravandi F,
Kantarjian HM
,
Bueso-Ramos C
, Zhang L,
Singh RR
,
Patel KP
,
Medeiros LJ
, Stingo F,
Routbort M
,
Cortes J
,
Luthra R
,
Khoury JD
. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
PMID:
25281355
; PMCID:
PMC4197326
.
Citations:
36
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Tam CS, O'Brien S, Plunkett W,
Wierda W
,
Ferrajoli A
, Wang X,
Do KA
,
Cortes J
,
Khouri I
,
Kantarjian H
, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64.
PMID:
25281606
; PMCID:
PMC4231417
.
Citations:
37
Fields:
Hem
Hematology
Translation:
Humans
Kantarjian H
,
Cortes JE
. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014 Sep 20; 32(27):3077.
PMID:
25002733
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Kadia TM
, Ravandi F, O'Brien S,
Cortes J
,
Kantarjian HM
. Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):139-51.
PMID:
25441110
; PMCID:
PMC4344862
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
Pemmaraju N
,
Kantarjian H
,
Kadia T
,
Cortes J
,
Borthakur G
, Newberry K,
Garcia-Manero G
, Ravandi F,
Jabbour E
, Dellasala S, Pierce S,
Verstovsek S
. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
PMID:
25441108
; PMCID:
PMC4344906
.
Citations:
31
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K,
Kantarjian H
, Louie AC, Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15; 121(2):234-42.
PMID:
25223583
; PMCID:
PMC5542857
.
Citations:
52
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Pemmaraju N
,
Cortes J
. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014; 132(3-4):298-306.
PMID:
25228555
.
Citations:
6
Fields:
Hem
Hematology
Translation:
Humans
Cortes JE
, Guilhot F, Pavlov D, Countouriotis AM, Gambacorti-Passerini C, Br?mmendorf TH, de Souza CA, Duvilli? L, Gogat K. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan; 168(1):69-81.
PMID:
25196702
; PMCID:
PMC4274978
.
Citations:
56
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Strati P,
Pemmaraju N
,
Estrov Z
, Cardenas-Turanzas M, Pierce S, Newberry KJ,
Daver N
,
Cortes J
,
Kantarjian H
,
Verstovsek S
. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6.
PMID:
25217891
; PMCID:
PMC4182146
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Zabriskie MS, Eide CA, Tantravahi SK, Estrada J, Khoury HJ, Larson RA,
Konopleva M
,
Cortes JE
,
Kantarjian H
,
Jabbour EJ
,
Kornblau SM
, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Druker BJ, Deininger MW, O'Hare T, Vellore NA, Nicolini FE, Hern?ndez-Boluda JC, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Baron R. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.
PMID:
25132497
; PMCID:
PMC4160372
.
Citations:
131
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Gambacorti-Passerini C,
Cortes JE
, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Khattry N,
Kantarjian HM
, Duvilli? L, Br?mmendorf TH. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct; 89(10):947-53.
PMID:
24944159
; PMCID:
PMC4305212
.
Citations:
33
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Borthakur G
,
Cortes JE
, Estey EE,
Jabbour E
, Faderl S, O'Brien S,
Garcia-Manero G
,
Kadia TM
, Wang X, Patel K,
Luthra R
, Koller C, Brandt M, Ravandi F,
Kantarjian H
. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014 Oct; 89(10):964-8.
PMID:
24990142
; PMCID:
PMC4431614
.
Citations:
19
Fields:
Hem
Hematology
Translation:
Humans
Jabbour E
,
Garcia-Manero G
, Cornelison AM,
Cortes JE
, Ravandi F,
Daver N
,
Kadia T
, Teng A,
Kantarjian H
. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4.
PMID:
24844364
; PMCID:
PMC4297591
.
Citations:
2
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Rytting ME
, Thomas DA, O'Brien SM,
Ravandi-Kashani F
,
Jabbour EJ
, Franklin AR,
Kadia TM
,
Pemmaraju N
,
Daver NG
,
Ferrajoli A
,
Garcia-Manero G
,
Konopleva MY
,
Cortes JE
,
Borthakur G
, Garris R, Cardenas-Turanzas M, Schroeder K,
Jorgensen JL
,
Kornblau SM
,
Kantarjian HM
. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
PMID:
25042398
; PMCID:
PMC4239168
.
Citations:
29
Fields:
Neo
Neoplasms
Translation:
Humans
Daver N
, Shastri A,
Kadia T
, Newberry K,
Pemmaraju N
,
Jabbour E
, Zhou L, Pierce S,
Cortes J
,
Kantarjian H
,
Verstovsek S
. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9.
PMID:
25047979
; PMCID:
PMC4157096
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
DiNardo CD
,
Tang G
,
Pemmaraju N
,
Wang SA
, Pike A,
Garcia-Manero G
,
Cortes J
,
Bueso-Ramos C
,
Kantarjian HM
. Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation. Clin Lymphoma Myeloma Leuk. 2015 Jan; 15(1):47-51.
PMID:
25081372
; PMCID:
PMC4849878
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK,
Cortes J
,
Kantarjian H
,
Andreeff M
, Frankel AE,
Konopleva M
. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74.
PMID:
24942980
; PMCID:
PMC4146738
.
Citations:
26
Fields:
Hem
Hematology
Translation:
Humans
Animals
Cells
Romo CG, Jain P,
Cortes JE
. Numb chin syndrome by precursor B acute lymphoblastic leukemia. Am J Hematol. 2014 Aug; 89(8):860-1.
PMID:
24850438
.
Citations:
3
Fields:
Hem
Hematology
Translation:
Humans
Mathisen MS,
Kantarjian HM
,
Cortes J
,
Jabbour EJ
. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014 Sep; 28(5):179-87.
PMID:
24984571
.
Citations:
12
Fields:
Hem
Hematology
Translation:
Humans
Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Inamoto Y, Hale GA, Aljurf MD,
Kamble RT
, Hsu JW, Pavletic SZ, Wirk B, Seftel MD, Lewis ID, Alyea EP,
Cortes J
, Kalaycio ME, Maziarz RT, Saber W. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8.
PMID:
24880021
; PMCID:
PMC4174349
.
Citations:
7
Fields:
Hem
Hematology
Tra
Transplantation
Translation:
Humans
Daver N
, Kim H,
Dinardo C
,
Jabbour E
,
Kadia T
,
Borthakur G
, Pierce S, Shan J, Cardenas-Turanzas M,
Cortes J
, Ravandi F,
Wierda W
,
Estrov Z
, Faderl S,
Wei Y
,
Kantarjian H
,
Garcia-Manero G
, Quint?s-Cardama A. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
PMID:
24875590
; PMCID:
PMC4167474
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
Gambacorti-Passerini C, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S,
Kantarjian HM
, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V,
Cortes JE
, Br?mmendorf TH. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul; 89(7):732-42.
PMID:
24711212
; PMCID:
PMC4173127
.
Citations:
39
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ,
Cortes JE
, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32.
PMID:
24777602
; PMCID:
PMC4054323
.
Citations:
30
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
Animals
Cells
Pemmaraju N
,
Kantarjian H
,
Andreeff M
,
Cortes J
, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Jul; 23(7):943-54.
PMID:
24749672
; PMCID:
PMC4109297
.
Citations:
16
Fields:
Dru
Drug Therapy
Translation:
Humans
Animals
Alvarado Y
,
Kantarjian HM
,
Luthra R
, Ravandi F,
Borthakur G
,
Garcia-Manero G
,
Konopleva M
,
Estrov Z
,
Andreeff M
,
Cortes JE
. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014 Jul 15; 120(14):2142-9.
PMID:
24737502
; PMCID:
PMC4124083
.
Citations:
58
Fields:
Neo
Neoplasms
Translation:
Humans
Lancet JE,
Cortes JE
, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22; 123(21):3239-46.
PMID:
24687088
; PMCID:
PMC4624448
.
Citations:
120
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Zhang W
, Gao C,
Konopleva M
, Chen Y,
Jacamo RO
,
Borthakur G
,
Cortes JE
, Ravandi F, Ramachandran A,
Andreeff M
. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014 May 01; 20(9):2363-74.
PMID:
24619500
; PMCID:
PMC4073635
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Jabbour E
,
Daver N
,
Champlin R
, Mathisen M,
Oran B
,
Ciurea S
,
Khouri I
, Cornelison AM, Ghanem H, Cardenas-Turanzas M,
Popat U
, Ravandi F, Giralt S,
Garcia-Manero G
,
Cortes J
,
Kantarjian H
, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
PMID:
24375514
; PMCID:
PMC4140180
.
Citations:
15
Fields:
Hem
Hematology
Translation:
Humans
Cells
Benjamini O, Dumlao TL,
Kantarjian H
, O'Brien S,
Garcia-Manero G
, Faderl S,
Jorgensen J
,
Luthra R
, Garris R, Thomas D,
Kebriaei P
,
Champlin R
,
Jabbour E
, Burger J,
Cortes J
, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.
PMID:
24779033
; PMCID:
PMC4196860
.
Citations:
13
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Shah NP,
Cortes JE
, Schiffer CA, le Coutre P,
Kantarjian HM
, Hochhaus A, Rousselot P,
Mohamed H
, Healey D, Cunningham M, Saglio G, Guilhot F, Br?mmendorf TH. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24.
PMID:
24569263
; PMCID:
PMC4915794
.
Citations:
57
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Talpaz M,
Kantarjian H
. Ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2014 02 06; 370(6):577.
PMID:
24499221
.
Citations:
7
Fields:
Med
Medicine (General)
Translation:
Humans
Gandhi V
, Plunkett W,
Cortes JE
. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
PMID:
24501394
; PMCID:
PMC4048124
.
Citations:
43
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
DiNardo CD
,
Patel KP
,
Garcia-Manero G
,
Luthra R
, Pierce S,
Borthakur G
,
Jabbour E
,
Kadia T
,
Pemmaraju N
,
Konopleva M
, Faderl S,
Cortes J
,
Kantarjian HM
, Ravandi F. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
PMID:
24138309
; PMCID:
PMC4139917
.
Citations:
26
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Nazha A,
Kantarjian HM
, Bhatt VR, Nogueras-Gonzalez G,
Cortes JE
,
Kadia T
,
Garcia-Manero G
, Abruzzo L,
Daver N
,
Pemmaraju N
, Quintas-Cardama A, Ravandi F, Keating M,
Borthakur G
. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71.
PMID:
24461514
; PMCID:
PMC4167660
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Choi S,
Kantarjian H
,
Jabbour E
,
Huang X
,
Cortes J
, Quint?s-Cardama A. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8.
PMID:
24594142
; PMCID:
PMC4099320
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Anzalone CL, Cohen PR, Kurzrock R,
Cortes JE
. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. Dermatol Online J. 2014 Jan 15; 20(1):21242.
PMID:
24456946
.
Citations:
Fields:
Der
Dermatology
Translation:
Humans
Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE,
Kantarjian HM
, Radich JP, Hughes TP,
Cortes JE
, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol. 2014; 99(5):616-24.
PMID:
24658916
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
Kantarjian HM
,
Cortes JE
, Kim DW, Khoury HJ, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C, Br?mmendorf TH. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27; 123(9):1309-18.
PMID:
24345751
; PMCID:
PMC4467890
.
Citations:
50
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Faderl S,
Balakrishnan K
, Thomas DA, Ravandi F,
Borthakur G
, Burger J,
Ferrajoli A
,
Cortes J
, O'Brien S,
Kadia T
, Feliu J, Plunkett W,
Gandhi V
,
Kantarjian HM
. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.
PMID:
24440659
; PMCID:
PMC4182922
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Pan R, Hogdal LJ, Benito JM, Bucci D,
Han L
,
Borthakur G
,
Cortes J
, DeAngelo DJ, Debose L, Mu H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Newman R, Park E,
Ruvolo PP
, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM,
Kantarjian H
,
Andreeff M
,
Konopleva M
, Letai AG, D?hner H, M?schen M. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75.
PMID:
24346116
; PMCID:
PMC3975047
.
Citations:
288
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Verstovsek S
, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P,
Cortes J
,
Kantarjian H
, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22.
PMID:
24374145
; PMCID:
PMC4414320
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ohanian M
,
Kantarjian HM
, Quintas-Cardama A,
Jabbour E
, Abruzzo L,
Verstovsek S
,
Borthakur G
, Ravandi F,
Garcia-Manero G
,
Champlin R
, Pierce S, Alattar ML, Trinh LX,
Luthra R
,
Ferrajoli A
,
Kadia T
, O'Brien S,
Cortes JE
. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
PMID:
24332214
; PMCID:
PMC3959284
.
Citations:
15
Fields:
Neo
Neoplasms
Translation:
Humans
DiNardo CD
,
Cortes JE
. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia. Expert Opin Investig Drugs. 2014 Feb; 23(2):265-72.
PMID:
24313331
.
Citations:
4
Fields:
Dru
Drug Therapy
Translation:
Humans
Animals
Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ,
Kamble RT
, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME,
Cortes J
, Maziarz RT, Gale RP, Saber W. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4.
PMID:
24321745
; PMCID:
PMC4026353
.
Citations:
8
Fields:
Hem
Hematology
Tra
Transplantation
Translation:
Humans
Akard LP,
Cortes JE
, Albitar M, Goldberg SL, Warsi G, Wetzler M, Ericson SG, Radich JP. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Arch Pathol Lab Med. 2014 Sep; 138(9):1186-92.
PMID:
24308645
.
Citations:
Fields:
Pat
Pathology
Translation:
Humans
CT
Clinical Trials
Jabbour E
,
Kantarjian HM
, Saglio G, Steegmann JL, Shah NP, Chuah C, Pavlovsky C,
Cortes J
, Baccarani M, Kim DW, Bradley-Garelik MB,
Mohamed H
, Wildgust M, Hochhaus A, Boqu? C, Mayer J. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23; 123(4):494-500.
PMID:
24311723
; PMCID:
PMC4190618
.
Citations:
146
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Williams LA
, Yucel E,
Cortes JE
,
Cleeland CS
. Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clin Investig (Lond). 2013 Dec 01; 3(12):1127-1138.
PMID:
24910769
; PMCID:
PMC4043382
.
Citations:
1
Jabbour EJ
,
Cortes JE
,
Kantarjian HM
. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013 Dec; 13(12):1433-52.
PMID:
24236822
; PMCID:
PMC4181370
.
Citations:
13
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Yang H
,
Bueso-Ramos C
, DiNardo C, Estecio MR, Davanlou M, Geng QR, Fang Z, Nguyen M, Pierce S,
Wei Y
,
Parmar S
,
Cortes J
,
Kantarjian H
,
Garcia-Manero G
. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014 Jun; 28(6):1280-8.
PMID:
24270737
; PMCID:
PMC4032802
.
Citations:
274
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Jabbour E
, Ghanem H,
Huang X
, Ravandi F,
Garcia-Manero G
, O'Brien S, Faderl S, Pierce S, Choi S,
Verstovsek S
, Brandt M,
Cortes J
,
Kantarjian H
. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.
PMID:
24447728
; PMCID:
PMC4098769
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Foran J, Ravandi F,
Wierda W
,
Garcia-Manero G
,
Verstovsek S
,
Kadia T
, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V,
Borthakur G
,
Cortes J
,
Kantarjian H
. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30.
PMID:
24355079
; PMCID:
PMC4096861
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Jain P, Romo CG, Khoury HJ,
Kantarjian H
,
Cortes J
. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. Haematologica. 2013 Nov; 98(11):e141-2.
PMID:
24186316
; PMCID:
PMC3815188
.
Citations:
1
Fields:
Hem
Hematology
Translation:
Humans
Cells
Benton CB
, Ravandi F,
Andreeff M
,
Kadia T
, Ruvolo V, Qiu P,
Wheeler DA
,
Garcia-Manero G
,
Cortes J
,
Kantarjian HM
,
Konopleva M
. Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma. 2014 Jun; 55(6):1431-4.
PMID:
24033106
; PMCID:
PMC4105975
.
Citations:
2
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Karjalainen K, Pasqualini R,
Cortes JE
,
Kornblau SM
, Lichtiger B, O'Brien S,
Kantarjian HM
, Sidman RL, Arap W, Koivunen E. Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia. Cancer. 2014 Feb 15; 120(4):589-602.
PMID:
24496871
; PMCID:
PMC4457455
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Jain P,
Kantarjian H
, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E,
Konopleva M
,
Cortes J
, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5.
PMID:
24157581
.
Citations:
19
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Kornblau SM
, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F,
Cortes J
,
Andreeff M
, Zhang N, Coombes KR. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One. 2013; 8(10):e78453.
PMID:
24223100
; PMCID:
PMC3816767
.
Citations:
22
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Cells
Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH,
Kamble RT
, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD,
Popat U
, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT,
Cortes J
, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
PMID:
24161923
; PMCID:
PMC3886623
.
Citations:
49
Fields:
Hem
Hematology
Tra
Transplantation
Translation:
Humans
Mesa RA,
Cortes J
. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013 Oct 22; 6:79.
PMID:
24283870
; PMCID:
PMC4222119
.
Citations:
21
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Strati P,
Kantarjian H
, Thomas D, O'Brien S,
Konoplev S
,
Jorgensen JL
,
Luthra R
, Abruzzo L,
Jabbour E
, Quintas-Cardama A,
Borthakur G
, Faderl S, Ravandi F,
Cortes J
. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014 Feb 01; 120(3):373-80.
PMID:
24151050
; PMCID:
PMC3946911
.
Citations:
17
Fields:
Neo
Neoplasms
Translation:
Humans
Luthra R
,
Patel KP
, Reddy NG, Haghshenas V,
Routbort MJ
, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F,
Cortes JE
,
Kantarjian HM
,
Medeiros LJ
,
Singh RR
. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.
PMID:
24142997
; PMCID:
PMC3943309
.
Citations:
77
Fields:
Hem
Hematology
Translation:
Humans
Jain P,
Kantarjian H
, Estey E, Pierce S,
Cortes J
, Lopez-Berestein G, Ravandi F. Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e47-9.
PMID:
24128595
; PMCID:
PMC4103408
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Jain P,
Kantarjian H
,
Patel K
, Faderl S,
Garcia-Manero G
, Benjamini O,
Borthakur G
,
Pemmaraju N
,
Kadia T
,
Daver N
, Nazha A,
Luthra R
, Pierce S,
Cortes J
, Ravandi F. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
PMID:
24004182
; PMCID:
PMC4143910
.
Citations:
16
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Jabbour E
,
Cortes J
, Ravandi F, O'Brien S,
Kantarjian H
. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83.
PMID:
24246694
; PMCID:
PMC4098770
.
Citations:
13
Fields:
Hem
Hematology
Translation:
Humans
Nazha A, Romo CG,
Kantarjian H
,
Cortes J
. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica. 2013 Oct; 98(10):e131.
PMID:
24091930
; PMCID:
PMC3789475
.
Citations:
6
Fields:
Hem
Hematology
Translation:
Humans
Cells
Garcia JB, Lei X,
Wierda W
,
Cortes JE
,
Dickey BF
,
Evans SE
,
Ost DE
. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013 Oct; 10(5):432-40.
PMID:
23987587
; PMCID:
PMC3960911
.
Citations:
30
Fields:
Pul
Pulmonary Medicine
Translation:
Humans
Takahashi K
,
Patel KP
,
Kantarjian H
,
Luthra R
, Pierce S,
Cortes J
,
Verstovsek S
. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6.
PMID:
24068492
; PMCID:
PMC3952679
.
Citations:
8
Fields:
Hem
Hematology
Translation:
Humans
Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y,
Kamble RT
, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J,
Cortes J
, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
PMID:
24065243
; PMCID:
PMC3854108
.
Citations:
56
Fields:
Hem
Hematology
Translation:
Humans
Yilmaz M,
Kantarjian H
,
Jabbour E
, O'Brien S,
Borthakur G
,
Verstovsek S
,
Garcia-Manero G
, Ravandi F, Burger J, Pierce S, Quintas-Cardama A,
Cortes J
. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9.
PMID:
24060289
; PMCID:
PMC3835390
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Grgurevic S, Rozovski U, Li P,
Estrov Z
,
Cortes J
, Quint?s-Cardama A. Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):681-5.
PMID:
24060288
; PMCID:
PMC4162086
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Falchi L,
Kantarjian HM
, Wang X, Verma D, O'Brien S,
Jabbour EJ
,
Ravandi-Kashani F
,
Borthakur G
,
Garcia-Manero G
,
Verstovsek S
,
Burger JA
,
Luthra R
,
Cortes JE
, Quint?s-Cardama A. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.
PMID:
23913852
; PMCID:
PMC3849405
.
Citations:
28
Fields:
Hem
Hematology
Translation:
Humans
Benjamini O,
Kantarjian H
, Rios MB,
Jabbour E
, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S,
Garcia-Manero G
, Ravandi F,
Borthakur G
, Quintas-Cardama A,
Cortes J
. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec; 55(12):2879-86.
PMID:
23927391
; PMCID:
PMC4127158
.
Citations:
13
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Nazha A,
Kantarjian H
, Ravandi F,
Huang X
, Choi S,
Garcia-Manero G
,
Jabbour E
,
Borthakur G
,
Kadia T
,
Konopleva M
,
Cortes J
,
Ferrajoli A
,
Kornblau S
,
Daver N
,
Pemmaraju N
,
Andreeff M
,
Estrov Z
, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
PMID:
23877926
; PMCID:
PMC4110914
.
Citations:
21
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S,
Cortes J
, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.
PMID:
23999433
; PMCID:
PMC3784537
.
Citations:
117
Fields:
Med
Medicine (General)
Translation:
Humans
Animals
Cells
Cortes JE
,
Kantarjian H
, Foran JM, Ghirdaladze D, Zodelava M,
Borthakur G
, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10; 31(29):3681-7.
PMID:
24002496
; PMCID:
PMC3804291
.
Citations:
159
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Chakhachiro ZI,
Zuo Z
, Aladily TN,
Kantarjian HM
,
Cortes JE
, Alayed K, Nguyen MH,
Medeiros LJ
,
Bueso-Ramos C
. CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias. Am J Clin Pathol. 2013 Sep; 140(3):370-8.
PMID:
23955456
.
Citations:
6
Fields:
Pat
Pathology
Translation:
Humans
Ghanem H, Cornelison AM,
Garcia-Manero G
,
Kantarjian H
, Ravandi F,
Kadia T
,
Cortes J
, O'Brien S, Brandt M,
Borthakur G
,
Jabbour E
. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94.
PMID:
23969308
; PMCID:
PMC4120258
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Strati P,
Daver N
, Ravandi F,
Pemmaraju N
, Pierce S,
Garcia-Manero G
, Nazha A,
Kadia T
,
Jabbour E
,
Borthakur G
, Faderl S, Quintas-Cardama A,
Kantarjian H
,
Cortes J
. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.
PMID:
23969309
; PMCID:
PMC4101888
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
Cherry M, Cardenas-Turanzas M, Pham H,
Kantarjian H
,
Cortes J
, Pierce S, Zhou L,
Verstovsek S
. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013 Nov; 37(11):1472-6.
PMID:
23993426
; PMCID:
PMC3818458
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Zheng W,
Medeiros LJ
,
Young KH
, Goswami M, Powers L,
Kantarjian HH
, Thomas DA,
Cortes JE
,
Wang SA
. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014 Mar; 55(3):624-7.
PMID:
23937105
; PMCID:
PMC4188389
.
Citations:
12
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Takahashi K
,
Pemmaraju N
, Strati P, Nogueras-Gonzalez G,
Ning J
,
Bueso-Ramos C
,
Luthra R
, Pierce S,
Cortes J
,
Kantarjian H
,
Garcia-Manero G
. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013 Oct 17; 122(16):2807-11; quiz 2920.
PMID:
23896412
; PMCID:
PMC3798995
.
Citations:
17
Fields:
Hem
Hematology
Translation:
Humans
Jabbour EJ
,
Cortes JE
,
Kantarjian HM
. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):515-29.
PMID:
23890944
; PMCID:
PMC4160831
.
Citations:
34
Fields:
Neo
Neoplasms
Translation:
Humans
Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW,
Cortes JE
, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res. 2013 Sep 15; 73(18):5775-86.
PMID:
23887971
; PMCID:
PMC3894913
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Daver N
, Shastri A,
Kadia T
, Quintas-Cardama A,
Jabbour E
,
Konopleva M
, O'Brien S, Pierce S, Zhou L,
Cortes J
,
Kantarjian H
,
Verstovsek S
. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4.
PMID:
23890523
; PMCID:
PMC4232180
.
Citations:
15
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Nazha A,
Kantarjian H
,
Cortes J
, Quint?s-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013 Oct; 14(14):1977-86.
PMID:
23875628
.
Citations:
4
Fields:
Pha
Pharmacology
Translation:
Humans
Animals
Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT,
Cortes J
, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013 Sep 12; 122(11):1974-82.
PMID:
23847196
; PMCID:
PMC3772501
.
Citations:
31
Fields:
Hem
Hematology
Translation:
Humans
Ravandi F,
Jorgensen JL
, Thomas DA, O'Brien S, Garris R, Faderl S,
Huang X
, Wen S,
Burger JA
,
Ferrajoli A
,
Kebriaei P
,
Champlin RE
,
Estrov Z
, Challagundla P, Wang SA,
Luthra R
,
Cortes JE
,
Kantarjian HM
. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.
PMID:
23836561
; PMCID:
PMC3976223
.
Citations:
77
Fields:
Hem
Hematology
Translation:
Humans
Cells
Ostronoff F, Othus M,
Kantarjian HM
, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS,
Cortes JE
, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2013 Oct; 163(1):130-2.
PMID:
23829510
; PMCID:
PMC4128010
.
Citations:
Fields:
Hem
Hematology
Translation:
Humans
Cells
Nazha A,
Kantarjian H
, Jain P, Romo C,
Jabbour E
, Quintas-Cardama A,
Luthra R
, Abruzzo L,
Borthakur G
, Ravandi F, Pierce S, O'Brien S,
Cortes J
. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica. 2013 Nov; 98(11):1686-8.
PMID:
23812943
; PMCID:
PMC3815167
.
Citations:
8
Fields:
Hem
Hematology
Translation:
Humans
Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE,
Cortes JE
, Hjorth-Hansen H, Hughes TP,
Kantarjian HM
, Kim DW, Larson RA, Lipton JH, Martinelli G, Mayer J, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Baccarani M, Guilhot F, Mahon FX, M?ller MC, Sau?ele S, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 08; 122(6):872-84.
PMID:
23803709
; PMCID:
PMC4915804
.
Citations:
652
Fields:
Hem
Hematology
Translation:
Humans
Jabbour E
,
Kantarjian H
, O'Brien S,
Kadia T
, Malik A, Welch MA, Teng A,
Cortes J
, Ravandi F,
Garcia-Manero G
. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):592-6.
PMID:
23790798
; PMCID:
PMC4120256
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Kantarjian HM
, O'Brien S,
Cortes J
. Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):530-3.
PMID:
23790799
; PMCID:
PMC3775965
.
Citations:
36
Fields:
Neo
Neoplasms
Translation:
Humans
Abdel-Wahab O, Manshouri T, Kilpivaara O,
Cortes J
, Roupie AL, Zhang SJ, Harris D,
Estrov Z
,
Kantarjian H
, Levine RL,
Verstovsek S
, Quint?s-Cardama A. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901.
PMID:
23782935
; PMCID:
PMC3739035
.
Citations:
87
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Williams LA
, Garcia Gonzalez AG, Ault P,
Mendoza TR
, Sailors ML, Williams JL, Huang F, Nazha A,
Kantarjian HM
,
Cleeland CS
,
Cortes JE
. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7.
PMID:
23777764
; PMCID:
PMC3731927
.
Citations:
38
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Cortes JE
, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M,
Kantarjian HM
. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):584-91.
PMID:
23787123
; PMCID:
PMC3775895
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Alayed K,
Medeiros LJ
, Schultz RA,
Cortes J
, Lu G,
Bueso-Ramos CE
,
Konoplev S
. Value of oligonucleotide-based array comparative genomic hybridization for diagnosis of acute promyelocytic leukemia in a patient negative for t(15;17)(q24.1;q21.2)/promyelocytic leukemia-retinoic acid receptor, alpha by conventional cytogenetics and fluorescence in situ hybridization. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):507-10.
PMID:
23770155
; PMCID:
PMC4259115
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Eghtedar A,
Kantarjian H
,
Jabbour E
, O'Brien S, Burton E,
Garcia-Manero G
,
Verstovsek S
, Ravandi F,
Borthakur G
,
Konopleva M
, Quintas-Cardama A,
Cortes J
. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.
PMID:
23770156
; PMCID:
PMC3752280
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
Othus M,
Kantarjian H
, Petersdorf S, Ravandi F, Godwin J,
Cortes J
, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E. Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014 Feb; 28(2):289-92.
PMID:
23760400
; PMCID:
PMC4457325
.
Citations:
56
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Pemmaraju N
, Tanaka MF, Ravandi F, Lin H,
Baladandayuthapani V
,
Rondon G
, Giralt SA, Chen J, Pierce S,
Cortes J
,
Kantarjian H
,
Champlin RE
, De Lima M,
Qazilbash MH
. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):485-92.
PMID:
23769669
; PMCID:
PMC4112369
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Daver N
, Liu Dumlao T, Ravandi F, Pierce S,
Borthakur G
,
Pemmaraju N
, Nazha A, Faderl S,
Jabbour E
,
Garcia-Manero G
,
Cortes J
,
Kantarjian H
, Quint?s-Cardama A. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
PMID:
23763915
; PMCID:
PMC4114766
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Cardenas-Turanzas M,
Ravandi-Kashani F
,
Cortes JE
,
Jabbour E
, Faderl S, Pierce SA,
Kantarjian H
. Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):579-83.
PMID:
23763918
; PMCID:
PMC4341913
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Nicolini FE, Khoury HJ, Akard L, Rea D,
Kantarjian H
, Baccarani M, Leonoudakis J, Craig A, Benichou AC,
Cortes J
. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul; 98(7):e78-9.
PMID:
23753022
; PMCID:
PMC3696599
.
Citations:
11
Fields:
Hem
Hematology
Translation:
Humans
Takahashi K
, Jabbour E, Wang X, Luthra R,
Bueso-Ramos C
,
Patel K
, Pierce S,
Yang H
,
Wei Y
, Daver N, Faderl S, Ravandi F,
Estrov Z
,
Cortes J
,
Kantarjian H
,
Garcia-Manero G
. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
PMID:
23774633
.
Citations:
25
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cortes JE
. A journey searching for a cure for leukemia. Interviewed by Natasha Galukande. Future Oncol. 2013 Jun; 9(6):785-7.
PMID:
23718297
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Jain P,
Kantarjian H
,
Cortes J
. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol. 2013 Jun; 14(2):127-43.
PMID:
23572291
.
Citations:
16
Fields:
Neo
Neoplasms
Translation:
Humans
Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Hochhaus A, Dufva IH, Kim DW,
Cortes J
, Mauro MJ, Chuah C, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Michallet M, Goldman J, Apperley JF,
Marin D
, Etienne G, M?ller MC, Labussi?re H, Morisset S, Maguer-Satta V, Mahon FX. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013 Oct; 98(10):1510-6.
PMID:
23716543
; PMCID:
PMC3789454
.
Citations:
24
Fields:
Hem
Hematology
Translation:
Humans
Lu G, Schulz RA,
Bueso-Ramos CE
,
Cortes JE
, Iris Wang X,
Medeiros LJ
,
Yin CC
. Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia. J Clin Pathol. 2013 Sep; 66(9):826-9.
PMID:
23703854
.
Citations:
Fields:
Pat
Pathology
Translation:
Humans
Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG,
Kantarjian H
,
Cortes JE
. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013 Aug; 162(4):548-52.
PMID:
23691988
; PMCID:
PMC3866040
.
Citations:
30
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Santos FP, Tam CS,
Kantarjian H
,
Cortes J
, Thomas D, Pollock R,
Verstovsek S
. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014 Jan; 55(1):121-7.
PMID:
23573823
; PMCID:
PMC3874259
.
Citations:
14
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Ravandi F,
Cortes J
,
Kantarjian H
. Is there a standard induction regimen for patients with AML? Lancet Oncol. 2013 Jun; 14(7):565-6.
PMID:
23664706
; PMCID:
PMC4111562
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Kantarjian H
, Thomas D,
Jorgensen J
,
Kebriaei P
,
Jabbour E
,
Rytting M
, York S, Ravandi F, Garris R, Kwari M, Faderl S,
Cortes J
,
Champlin R
, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.
PMID:
23633004
; PMCID:
PMC3720844
.
Citations:
95
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Farroni JS, Zwelling L,
Cortes J
,
Kantarjian H
. Saving Medicare through patient-centered changes--the case of injectables. N Engl J Med. 2013 Apr 25; 368(17):1572-3.
PMID:
23614583
.
Citations:
1
Fields:
Med
Medicine (General)
Translation:
Humans
Jain P,
Kantarjian H
, Nazha A, O'Brien S,
Jabbour E
, Romo CG, Pierce S, Cardenas-Turanzas M,
Verstovsek S
,
Borthakur G
, Ravandi F,
Cortes J
, Quint?s-Cardama A. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74.
PMID:
23620574
; PMCID:
PMC3743466
.
Citations:
51
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Sonnichsen D, Dorer DJ,
Cortes J
, Talpaz M, Deininger MW, Shah NP,
Kantarjian HM
, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1599-607.
PMID:
23609479
; PMCID:
PMC3668123
.
Citations:
11
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S,
Daver N
,
Garcia-Manero G
, Faderl S, Nazha A,
Konopleva M
,
Borthakur G
,
Burger J
,
Kadia T
, Dellasala S,
Andreeff M
,
Cortes J
,
Kantarjian H
, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.
PMID:
23613521
; PMCID:
PMC3674666
.
Citations:
158
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Mouhayar E
, Durand JB,
Cortes J
. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf. 2013 Sep; 12(5):687-96.
PMID:
23560546
.
Citations:
9
Fields:
Dru
Drug Therapy
Pha
Pharmacology
Translation:
Humans
Takahashi K
,
Kantarjian H
,
Pemmaraju N
,
Andreeff M
,
Borthakur G
, Faderl S,
Garcia-Manero G
, Pierce S,
Luthra R
, Cardenas-Turanzas M,
Estrov Z
, Ravandi F,
Cortes J
. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.
PMID:
23530930
; PMCID:
PMC4068703
.
Citations:
11
Fields:
Hem
Hematology
Translation:
Humans
Cells
Al-Kali A,
Luthra R
,
Bueso-Ramos C
, Pierce S,
Kadia T
,
Borthakur G
,
Estrov Z
,
Jabbour E
, Faderl S, Ravandi F,
Cortes J
, Tefferi A,
Kantarjian H
,
Garcia-Manero G
, Quint?s-Cardama A. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am J Hematol. 2013 May; 88(5):365-9.
PMID:
23512829
; PMCID:
PMC4089101
.
Citations:
13
Fields:
Hem
Hematology
Translation:
Humans
Cortes J
, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE,
Kantarjian HM
, Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May; 88(5):350-4.
PMID:
23468307
; PMCID:
PMC5558840
.
Citations:
22
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Cortes J
, Feldman E, Yee K, Rizzieri D, Advani AS, Charman A, Spruyt R, Toal M,
Kantarjian H
. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013 Apr; 14(4):354-62.
PMID:
23453583
; PMCID:
PMC5557006
.
Citations:
14
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Nazha A,
Estrov Z
,
Cortes J
,
Bueso-Ramos CE
,
Kantarjian H
,
Verstovsek S
. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma. 2013 Nov; 54(11):2537-9.
PMID:
23343175
; PMCID:
PMC4135587
.
Citations:
6
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Kantarjian H
, Pierce S,
Cortes J
,
Verstovsek S
, Quint?s-Cardama A. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):315-318.e2.
PMID:
23391717
; PMCID:
PMC3901422
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Ohanian M
, Faderl S, Ravandi F,
Pemmaraju N
,
Garcia-Manero G
,
Cortes J
,
Estrov Z
. Is acute myeloid leukemia a liquid tumor? Int J Cancer. 2013 Aug 01; 133(3):534-43.
PMID:
23280377
; PMCID:
PMC3904286
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
Takahashi K
,
Cortes J
, Pierce S, Abruzzo L,
Kantarjian H
,
Verstovsek S
. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res. 2013 May; 37(5):552-5.
PMID:
23391517
; PMCID:
PMC4408989
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Sever M,
Cortes J
,
Kantarjian H
,
Verstovsek S
, Quint?s-Cardama A. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. Leuk Lymphoma. 2013 Sep; 54(9):1959-64.
PMID:
23278641
; PMCID:
PMC5127201
.
Citations:
3
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Jabbour E
,
Kantarjian H
, Ghanem H, O'Brien S, Quintas-Cardama A,
Garcia-Manero G
, Cardenas M,
Cortes J
. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):302-6.
PMID:
23318257
; PMCID:
PMC4160838
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Zheng W,
Medeiros LJ
, Hu Y, Powers L,
Cortes JE
,
Ravandi-Kashani F
,
Kantarjian HH
, Wang SA. CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):307-14.
PMID:
23313069
; PMCID:
PMC4188388
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Mathisen MS,
Kantarjian H
,
Jabbour E
,
Garcia-Manero G
, Ravandi F, Faderl S,
Borthakur G
,
Cortes JE
, Quint?s-Cardama A. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):139-43.
PMID:
23276886
; PMCID:
PMC4114759
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Malik A, Shoukier M,
Garcia-Manero G
,
Wierda W
,
Cortes J
, Bickel S, Keating MJ,
Estrov Z
. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5.
PMID:
23265768
; PMCID:
PMC3860181
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Jabbour E
,
Garcia-Manero G
, Ravandi F, Faderl S, O'Brien S, Fullmer A,
Cortes JE
,
Wierda W
,
Kantarjian H
. Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):131-8.
PMID:
23260600
; PMCID:
PMC4098775
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Bhatt VR,
Kantarjian H
,
Cortes JE
, Ravandi F,
Borthakur G
. Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):153-8.
PMID:
23266036
; PMCID:
PMC3854973
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
Bhamidipati PK,
Jabbour E
,
Konoplev S
,
Estrov Z
,
Cortes J
,
Daver N
. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):342-6.
PMID:
23246163
; PMCID:
PMC4019340
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Chen Y, Wang H,
Kantarjian H
,
Cortes J
. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013 Jul; 54(7):1411-7.
PMID:
23121646
; PMCID:
PMC5525971
.
Citations:
39
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cortes JE
,
Kantarjian H
, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI,
Rivera VM
, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88.
PMID:
23190221
; PMCID:
PMC3777383
.
Citations:
272
Fields:
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Chen Y,
Kantarjian H
, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M,
Kebriaei P
, Jabbour E, Daver N, Kadia T,
Estrov Z
,
Garcia-Manero G
,
Cortes J
, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
PMID:
23135353
; PMCID:
PMC4181539
.
Citations:
22
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Cortes J
. CML: the good, the better, and the difficult choices. Blood. 2012 Nov 08; 120(19):3866-7.
PMID:
23144157
.
Citations:
1
Fields:
Hem
Hematology
Translation:
Humans
Talpaz M, Hehlmann R, Mercer J,
Cortes J
, Quint?s-Cardama A. Re-emergence of interferon-a in the treatment of chronic myeloid leukemia. Leukemia. 2013 Apr; 27(4):803-12.
PMID:
23238589
; PMCID:
PMC3703612
.
Citations:
58
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Jabbour E
, le Coutre PD,
Cortes J
, Giles F,
Bhalla KN
, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M,
Kantarjian HM
. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13.
PMID:
23174881
; PMCID:
PMC4140185
.
Citations:
7
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Zhou Y,
Jorgensen JL
, Wang SA, Ravandi F,
Cortes J
,
Kantarjian HM
,
Medeiros LJ
,
Konoplev S
. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012 Nov; 138(5):744-50.
PMID:
23086776
.
Citations:
6
Fields:
Pat
Pathology
Translation:
Humans
Strati P,
Cortes J
, Faderl S,
Kantarjian H
,
Verstovsek S
. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):287-91.
PMID:
23123105
; PMCID:
PMC4445419
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes J
. Bosutinib in the treatment of chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012 Nov; 10(11):736-7.
PMID:
23271260
.
Citations:
1
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Daver N
, Strati P,
Jabbour E
,
Kadia T
,
Luthra R
,
Wang S
, Patel K, Ravandi F,
Cortes J
, Qin Dong X,
Kantarjian H
,
Garcia-Manero G
. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
PMID:
23115106
; PMCID:
PMC4085099
.
Citations:
31
Fields:
Hem
Hematology
Translation:
Humans
Cells
Kantarjian HM
, Larson RA, Deering KL, Mauro MJ, Cort?s JE. Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54.
PMID:
23103085
; PMCID:
PMC3645375
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
Jabbour E
,
Morris V
,
Kantarjian H
,
Yin CC
, Burton E,
Cortes J
. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
PMID:
23086624
; PMCID:
PMC4195445
.
Citations:
8
Fields:
Hem
Hematology
Translation:
Humans
Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S,
Borthakur G
,
Garcia-Manero G
,
Cortes J
,
Kantarjian H
, Quint?s-Cardama A. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012 Dec 06; 120(24):4840-5.
PMID:
23071272
; PMCID:
PMC3952725
.
Citations:
81
Fields:
Hem
Hematology
Translation:
Humans
Cells
Cortes J
, Radich J, Mauro MJ. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2012 Oct; 10(10 Suppl 19):1-16.
PMID:
23187745
.
Citations:
1
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cortes J
, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012 Oct 01; 10 Suppl 3:S1-S13.
PMID:
23055247
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
Ohanian M
,
Borthakur G
, Quintas-Cardama A, Mathisen M,
Estrov Z
,
Pemmaraju N
, Cort?s JE. Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):93-6.
PMID:
23017332
; PMCID:
PMC4151170
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes J
, Santos FP. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Pharmacother. 2012 Nov; 13(16):2381-95.
PMID:
22992064
.
Citations:
3
Fields:
Pha
Pharmacology
Translation:
Humans
Animals
Cortes JE
, Kim DW,
Kantarjian HM
, Dyagil I, Griskevicius L, Malhotra H, Powell C, Countouriotis AM, Gambacorti-Passerini C, Br?mmendorf TH, Gogat K. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 01; 30(28):3486-92.
PMID:
22949154
; PMCID:
PMC4979199
.
Citations:
154
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hoehn D,
Medeiros LJ
,
Kantarjian HM
,
Cortes JE
, Wang X,
Bueso-Ramos CE
. Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Hum Pathol. 2012 Dec; 43(12):2354-9.
PMID:
22939577
.
Citations:
4
Fields:
Pat
Pathology
Translation:
Humans
Cortes J
, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE,
Kantarjian H
, Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27; 120(13):2573-80.
PMID:
22896000
; PMCID:
PMC4916583
.
Citations:
59
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Borthakur G
, Rosenblum MG, Talpaz M,
Daver N
, Ravandi F, Faderl S, Freireich EJ,
Kadia T
,
Garcia-Manero G
,
Kantarjian H
,
Cortes JE
. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21.
PMID:
22875630
; PMCID:
PMC3561428
.
Citations:
28
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X,
Cortes J
, Baccarani M,
Kantarjian HM
. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
PMID:
22763385
.
Citations:
72
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Verstovsek S
,
Kantarjian HM
,
Estrov Z
,
Cortes JE
, Thomas DA,
Kadia T
, Pierce S,
Jabbour E
,
Borthakur G
, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
PMID:
22718840
; PMCID:
PMC4081158
.
Citations:
82
Fields:
Hem
Hematology
Translation:
Humans
Chen Y,
Kantarjian H
, Wang H,
Cortes J
, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8.
PMID:
22707337
; PMCID:
PMC4180246
.
Citations:
25
Fields:
Neo
Neoplasms
Translation:
Humans
Warren M,
Luthra R
,
Yin CC
, Ravandi F,
Cortes JE
,
Kantarjian HM
,
Medeiros LJ
,
Zuo Z
. Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. Mod Pathol. 2012 Oct; 25(10):1405-12.
PMID:
22684224
.
Citations:
17
Fields:
Pat
Pathology
Translation:
Humans
Boumber Y,
Kantarjian H
,
Jorgensen J
, Wen S, Faderl S, Castoro R, Autry J,
Garcia-Manero G
, Borthakur G, Jabbour E,
Estrov Z
,
Cortes J
, Issa JP, Ravandi F. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia. 2012 Nov; 26(11):2428-31.
PMID:
22665218
; PMCID:
PMC3981542
.
Citations:
20
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Chacar C,
Jabbour E
, Ravandi F,
Borthakur G
,
Kadia T
,
Estrov Z
, Rios MB,
Cortes J
,
Kantarjian H
. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):197-200.
PMID:
22578814
; PMCID:
PMC4050633
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Carter BZ
, Qiu Y,
Huang X
, Diao L, Zhang N, Coombes KR, Mak DH,
Konopleva M
,
Cortes J
,
Kantarjian HM
,
Mills GB
,
Andreeff M
,
Kornblau SM
. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80.
PMID:
22645176
; PMCID:
PMC3390955
.
Citations:
49
Fields:
Hem
Hematology
Translation:
Humans
Cells
Singh RR, Bains A,
Patel KP
, Rahimi H, Barkoh BA, Paladugu A, Bisrat T,
Ravandi-Kashani F
,
Cortes JE
,
Kantarjian HM
,
Medeiros LJ
,
Luthra R
. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45.
PMID:
22642896
; PMCID:
PMC5707199
.
Citations:
12
Fields:
Mol
Molecular Biology
Translation:
Humans
Kantarjian H
,
Cortes J
, Quint?s-Cardama A. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):337-40.
PMID:
22633167
.
Citations:
45
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes J
,
Kantarjian H
. How I treat newly diagnosed chronic phase CML. Blood. 2012 Aug 16; 120(7):1390-7.
PMID:
22613793
; PMCID:
PMC4916560
.
Citations:
46
Fields:
Hem
Hematology
Translation:
Humans
Borthakur G
,
Kantarjian H
,
Patel KP
, Ravandi F, Qiao W, Faderl S,
Kadia T
,
Luthra R
, Pierce S,
Cortes JE
. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22.
PMID:
22605576
; PMCID:
PMC4184417
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Garcia-Manero G
, Tambaro FP, Bekele NB,
Yang H
, Ravandi F,
Jabbour E
,
Borthakur G
,
Kadia TM
,
Konopleva MY
, Faderl S,
Cortes JE
, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M,
Kantarjian HM
. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012 Jun 20; 30(18):2204-10.
PMID:
22585696
; PMCID:
PMC4879705
.
Citations:
71
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Chen Y,
Kantarjian H
,
Estrov Z
, Faderl S, Ravandi F, Rey K,
Cortes J
,
Borthakur G
. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):341-4.
PMID:
22579233
; PMCID:
PMC4103411
.
Citations:
14
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Kadia TM
,
Kantarjian H
,
Kornblau S
,
Borthakur G
, Faderl S, Freireich EJ,
Luthra R
,
Garcia-Manero G
, Pierce S,
Cortes J
, Ravandi F. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer. 2012 Nov 15; 118(22):5550-9.
PMID:
22569880
; PMCID:
PMC3416961
.
Citations:
19
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Ohanian M
,
Cortes J
,
Kantarjian H
,
Jabbour E
. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin Pharmacother. 2012 May; 13(7):927-38.
PMID:
22519766
.
Citations:
21
Fields:
Pha
Pharmacology
Translation:
Humans
Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G,
Cortes J
,
Kantarjian HM
, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8.
PMID:
22627678
; PMCID:
PMC4118284
.
Citations:
114
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Jabbour E
,
Garcia-Manero G
,
Cortes J
, Ravandi F, Plunkett W,
Gandhi V
, Faderl S, O'Brien S,
Borthakur G
,
Kadia T
,
Burger J
,
Konopleva M
, Brandt M,
Huang X
,
Kantarjian H
. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
PMID:
22534616
; PMCID:
PMC3859239
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Nazha A,
Cortes J
, Faderl S, Pierce S,
Daver N
,
Kadia T
,
Borthakur G
,
Luthra R
,
Kantarjian H
, Ravandi F. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5.
PMID:
22532519
; PMCID:
PMC3409823
.
Citations:
19
Fields:
Hem
Hematology
Translation:
Humans
Cells
Qiu YH,
Post SM
, Zhang Y,
Creighton CJ
,
Cortes J
,
Kornblau SM
, Quint?s-Cardama A. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer. 2012 Nov 01; 118(21):5283-92.
PMID:
22517119
; PMCID:
PMC3435477
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Kantarjian H
,
Estrov Z
,
Borthakur G
,
Cortes J
,
Verstovsek S
, Quint?s-Cardama A. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012 Sep; 36(9):1124-7.
PMID:
22475363
; PMCID:
PMC4152772
.
Citations:
31
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Daver N
,
Cortes J
. Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62.
PMID:
22507781
.
Citations:
16
Fields:
Hem
Hematology
Translation:
Humans
Animals
Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J,
Cortes J
, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1446-54.
PMID:
22449610
; PMCID:
PMC3499973
.
Citations:
7
Fields:
Hem
Hematology
Tra
Transplantation
Translation:
Humans
Cells
Jabbour E
,
Cortes J
, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S,
Garcia-Manero G
,
Kantarjian H
. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood. 2012 May 10; 119(19):4524-6.
PMID:
22431574
; PMCID:
PMC3362365
.
Citations:
27
Fields:
Hem
Hematology
Translation:
Humans
Tanaka MF,
Kantarjian H
,
Cortes J
,
Ohanian M
,
Jabbour E
. Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother. 2012 Apr; 13(6):815-28.
PMID:
22429140
.
Citations:
4
Fields:
Pha
Pharmacology
Translation:
Humans
Eghtedar A,
Verstovsek S
,
Estrov Z
,
Burger J
,
Cortes J
, Bivins C, Faderl S,
Ferrajoli A
,
Borthakur G
, George S, Scherle PA, Newton RC,
Kantarjian HM
, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.
PMID:
22422826
; PMCID:
PMC4081383
.
Citations:
85
Fields:
Hem
Hematology
Translation:
Humans
Cells
CT
Clinical Trials
Candelaria M, Labardini J, Gonzalez-Fierro A, Taja-Chayeb L,
Cortes J
, Gordillo-Bastidas D, Cervera E, L?pez-Navarro O, Due?as-Gonz?lez A. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):207-12.
PMID:
22420986
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Kantarjian H
,
Cortes J
, Quint?s-Cardama A. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. Drugs Today (Barc). 2012 Mar; 48(3):177-88.
PMID:
22462037
.
Citations:
2
Fields:
Dru
Drug Therapy
Translation:
Humans
Animals
Kantarjian H
, O'Brien S,
Garcia-Manero G
, Faderl S, Ravandi F,
Jabbour E
, Shan J,
Cortes J
. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer. 2012 Jun 15; 118(12):3116-22.
PMID:
22370904
; PMCID:
PMC3370116
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Khoury HJ,
Cortes JE
,
Kantarjian HM
, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Br?mmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12; 119(15):3403-12.
PMID:
22371878
; PMCID:
PMC4916559
.
Citations:
106
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Kantarjian H
, Thomas D,
Jorgensen J
,
Jabbour E
,
Kebriaei P
,
Rytting M
, York S, Ravandi F, Kwari M, Faderl S, Rios MB,
Cortes J
,
Fayad L
, Tarnai R, Wang SA,
Champlin R
, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.
PMID:
22357140
.
Citations:
136
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hughes TP,
Cortes J
, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y, Guilhot F. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012 May; 97(5):731-8.
PMID:
22315495
; PMCID:
PMC3342976
.
Citations:
36
Fields:
Hem
Hematology
Translation:
Humans
Huang X
,
Cortes J
,
Kantarjian H
. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012 Jun 15; 118(12):3123-7.
PMID:
22294282
; PMCID:
PMC3342429
.
Citations:
95
Fields:
Neo
Neoplasms
Translation:
Humans
Fava C,
Kantarjian H
,
Cortes J
. Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk. 2012 Apr; 12(2):79-87.
PMID:
22285607
; PMCID:
PMC5539978
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Cortes J
. Chronic myeloid leukemia: the race is yet to be won. CMAJ. 2012 May 15; 184(8):857-8.
PMID:
22271914
; PMCID:
PMC3348186
.
Citations:
Fields:
Med
Medicine (General)
Translation:
Humans
Pemmaraju N
,
Kantarjian H
, Shan J,
Jabbour E
, Quintas-Cardama A,
Verstovsek S
, Ravandi F,
Wierda W
, O'Brien S,
Cortes J
. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35.
PMID:
22271898
; PMCID:
PMC3396674
.
Citations:
31
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Eghtedar A,
Borthakur G
, Ravandi F,
Jabbour E
,
Cortes J
, Pierce S,
Kantarjian H
,
Garcia-Manero G
. Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. Am J Hematol. 2012 Mar; 87(3):317-8.
PMID:
22228403
; PMCID:
PMC4221258
.
Citations:
3
Fields:
Hem
Hematology
Translation:
Humans
Cells
Kantarjian H
, O'Brien S,
Jabbour E
,
Garcia-Manero G
, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S,
Kadia T
,
Borthakur G
,
Huang X
,
Champlin R
, Talpaz M,
Cortes J
. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7.
PMID:
22228624
; PMCID:
PMC3311242
.
Citations:
108
Fields:
Hem
Hematology
Translation:
Humans
Cortes JE
. Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia. J Clin Oncol. 2012 Jan 20; 30(3):223-4.
PMID:
22184376
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Kantarjian HM
, Shah NP,
Cortes JE
, Baccarani M, Agarwal MB, Wang J, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A, Undurraga MS, Ipi?a JJ. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 02; 119(5):1123-9.
PMID:
22160483
; PMCID:
PMC4916556
.
Citations:
195
Fields:
Hem
Hematology
Translation:
Humans
CT
Clinical Trials
Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M,
Cortes J
,
Kantarjian HM
, le Coutre PD. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012 Jun; 26(6):1189-94.
PMID:
22076466
.
Citations:
24
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Al-Kali A,
Konoplev S
, Lin E,
Kadia T
, Faderl S, Ravandi F, Ayoubi M, Brandt M,
Cortes JE
,
Kantarjian H
,
Borthakur G
. Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. Haematologica. 2012 Feb; 97(2):235-40.
PMID:
22058194
; PMCID:
PMC3269483
.
Citations:
4
Fields:
Hem
Hematology
Translation:
Humans
Kantarjian H
,
Cortes J
, Santos FP, Quint?s-Cardama A. Evolution of therapies for chronic myelogenous leukemia. Cancer J. 2011 Nov-Dec; 17(6):465-76.
PMID:
22157290
; PMCID:
PMC3243359
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Mak DH, Wang RY, Schober WD,
Konopleva M
,
Cortes J
,
Kantarjian H
,
Andreeff M
, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 2012 Apr; 26(4):788-94.
PMID:
22033489
; PMCID:
PMC3598156
.
Citations:
19
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Ravandi F, Patel K,
Luthra R
, Faderl S,
Konopleva M
,
Kadia T
, Brandt M, Pierce S,
Kornblau S
,
Andreeff M
, Wang X,
Garcia-Manero G
,
Cortes J
,
Kantarjian H
. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 2012 May 15; 118(10):2665-73.
PMID:
22020636
; PMCID:
PMC4060157
.
Citations:
22
Fields:
Neo
Neoplasms
Translation:
Humans
Jabbour E
, Parikh SA,
Kantarjian H
,
Cortes J
. Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am. 2011 Oct; 25(5):981-95, v.
PMID:
22054730
; PMCID:
PMC4428141
.
Citations:
16
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans